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ABSTRACT 
Clark H. Cunningham: Detection and Population Genetics of the Plasmodium falciparum dhps 581G Variant 
Associated with High-Level Sulfadoxine Resistance in the Democratic Republic of the Congo 
(Under the direction of Jonathan Juliano) 
Each year, over 125 million women in the Democratic Republic of the Congo (DRC) are at risk for 
malaria in pregnancy, representing a significant source of morbidity and mortality to both mothers and 
their children. To prevent malaria in pregnancy, sulfadoxine-pyrimethamine is used throughout sub-
Saharan Africa as a safe and effective form of chemoprophylaxis. However, high-level sulfadoxine 
resistance threatens to abrogate these protective effects, especially the spread of the single nucleotide 
variant dihydropteroate synthetase (dhps) 581G. To address this concern, we aimed to develop a novel 
molecular diagnostic capable of detecting this variant and to study the population genetics surrounding it 
within the DRC. First, we developed a suite of CRISPR-based diagnostics based on the platform 
SHERLOCK, or Specific High-Sensitivity Enzymatic Reporter UnLOCKing. We developed SHERLOCK 
assays capable of detecting all Plasmodium species known to cause human malaria and species-specific 
detection of P. vivax and P. falciparum, the species responsible for the majority of malaria cases 
worldwide. We found that our suite of Plasmodium SHERLOCK assays achieved low limits of detection in 
vitro comparable with other molecular diagnostics, and high sensitivity and specificity against a diverse 
panel of clinical isolates. Next, we developed a SHERLOCK assay capable of detecting the dhps 581G 
variant. We found that our dhps single nucleotide variant SHERLOCK assay achieved good sensitivity 
and high specificity when applied to a panel of deep-sequenced clinical samples, with false-negative calls 
only at low parasite densities. Finally, we conducted whole genome sequencing on a panel of clinical 
isolates from the Democratic Republic of the Congo, Ghana, and Tanzania to study the impact of the 
dhps 581G variant on P. falciparum population structure within the DRC. In contrast with other recent 
work, we did not find significant contribution to population structure from the dhps locus. We then   
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examined the extended haplotype surrounding the dhps locus and found no evidence of a recent hard 
selective sweep. Rather, we found the dhps 581G variant on multiple extended haplotypes from different 
locations, consistent with a soft selective sweep at this locus. 
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CHAPTER 1: INTRODUCTION TO MALARIA EPIDEMIOLOGY, PATHOGENESIS, AND ANTIFOLATE 
RESISTANCE 
1.1 Epidemiology of malaria 
Malaria is an infectious disease caused by protozoan parasites of the genus Plasmodium [1,2]. 
Malaria has been a consequential force throughout human history; it has turned the tides of wars, shaped 
human evolution, and inspired the gin and tonic mixed drink [3–5]. Despite over a century of research and 
public health efforts, malaria remains one of the most significant causes of human morbidity and mortality 
worldwide [6]. In 2019, an estimated 229 million cases of malaria resulted in 409,000 deaths worldwide 
[7]. One particular type of malaria, malaria in pregnancy, is a major source of maternal death and 
miscarriage as well as infant growth stunting and developmental delay [8,9]. The burden of malaria is not 
evenly distributed throughout the world. Rather, malaria is most prevalent in low and middle-income 
countries in the tropics and especially sub-Saharan Africa, where an estimated 93% of cases and 94% of 
deaths occur [7]. 
From antiquity until the late 19th century, malaria was hypothesized to be caused by noxious 
airborne miasmas emanating from wetlands and marshes; the name malaria is derived from “mala aira” or 
“bad air” in Italian [10]. However, we now know that P. falciparum is transmitted to humans through 
mosquitoes as an intermediate host, specifically female mosquitoes of the Anopheles genus [11,12]. At 
the time of this discovery, malaria was endemic throughout most of the subtropical regions of the world, 
including the east coast of the United States, the Mediterranean, and northern Australia [10]. Since the 
19th century and especially in the second half of the 20th century, tremendous progress has been made 
in restricting the geographic range of malaria, largely due to economic development, changes in land use, 
vector control, and improved housing and public health measures [13]. Today, malaria is no longer 
endemic in the aforementioned regions and its geographic range has receded greatly, with almost 85% of 
global malaria cases located in 18 countries in sub-Saharan African and in India [7]. Despite the global 
progress in malaria eradication, the Democratic Republic of the Congo (DRC), a central African country 
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home to over 101 million people, remains one of the most malarious regions of the world, with 97% of the 
country’s population living in a high transmission area (>1 annual cases per 1,000 population ) [14,15].  
Beyond its health effects, malaria inflicts a tremendous economic burden and hinders 
development in countries where it is endemic. On average, every 10% increase in the annual incidence of 
malaria is associated with a per capita income decrease of 0.3% and a per capita income growth 
decrease of 0.11% [16]. In response to the magnitude of these public health and economic 
consequences, the World Health Organization (WHO) has recognized malaria elimination as a global 
health priority and the international community has made significant investments in malaria control, 
reaching $2.7 billion annually by 2018 [7,17]. These investments have been successful at reducing the 
burden of malaria; between 2010 and 2018 malaria incidence decreased by an estimated 9% (251 million 
to 228 million) and malaria deaths decreased by an estimated 31% (585,000 to 405,000) [7]. Additionally, 
between 2005 and 2015, the number of years of life lost worldwide due to malaria decreased by 40.1%, 
the largest decrease in any of the leading 30 causes of years of life lost [6].  
However, improvements in malaria control have plateaued since 2016 and portend to reverse if 
efforts to prevent and treat malaria are not sustained and improved [7]. This stalling and even reversal in 
malaria control efforts is exemplified by the DRC. The DRC is a global hotspot for malaria; it has 12% of 
the world’s malaria cases and 11% of deaths despite having only 1.3% of the world’s population [14,15]. 
Despite years of decreasing malaria incidence, these trends have reversed since 2014 and threaten to 
worsen if action is not taken [7,18].  
1.2 P. falciparum biology and life cycle 
Malaria is not unique to humans; parasites of the genus Plasmodium infect a wide variety of 
organisms including non-human primates, birds, and reptiles [19]. Plasmodia belong to the phylum 
Apicomplexa, which contains other parasitic protozoa including Toxoplasma gondii and Cryptosporidium 
parvum. Apicomplexa are characterized by the presence of the apicoplast, a membrane-bound organelle 
descendant from the ancestral endosymbiosis of a red alga [20–22]. Despite subsequent loss of 
photosynthetic activity, apicoplasts are essential for parasite viability and are involved in biosynthesis of 
isoprenoid precursors, fatty acids, and heme biosynthesis in concert with the mitochondria [20–22].  
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Human malaria is caused by six species of Plasmodium: P. falciparum, vivax, malariae, ovale 
curtisi, ovale wallikeri, and knowlesi [23]. P. falciparum is the most common and deadly species of 
Plasmodium in humans and accounts for 99.7% of cases and nearly all deaths in sub-Saharan Africa, 
while P. vivax is the second most common species and is responsible for 50% of cases in Southeast Asia 
and 75% of cases in Central and South America [7]. Distinct from the other six human-infecting 
Plasmodium species, P. knowlesi requires a non-human primate as an intermediate host [24,25]. 
Evolutionarily, P. falciparum and P. vivax diverged approximately 10 million years ago from parasites that 
infected African apes, with P. falciparum in its current form evolving relatively recently in the last 10,000 
years [26,27]. While P. vivax is less common in sub-Saharan Africa due to the evolution of Duffy 
negativity, low levels of endemic P. vivax continue to persist in some countries [28,29].  
The life cycle of P. falciparum is complex and consists of multiple phases in both the mosquito 
and human host [9,30]. Human infection begins with a bite from an infected female Anopheles mosquito, 
which releases on the order of tens of sporozoites into the dermis [31]. Injected sporozoites migrate from 
the dermis into the capillaries, a process for which Trap-like protein is necessary [31]. Sporozoites that 
enter the blood migrate to the liver and cross the sinusoidal barrier between the blood and hepatocytes 
composed of endothelial and Kupffer cells through a process called traversal [32]. Traversal involves the 
formation of a transient vacuole to evade host lysosome fusion and requires the proteins sporozoite 
microneme proteins essential for traversal 1 and 2, cell traversal protein for ookinetes and sporozoites, 
phospholipase, and gamete egress and sporozoite traversal protein [31]. Sporozoites then use sporozoite 
microneme protein essential for traversal coupled with pH chemotaxis to exit the transient vacuole and 
proceed to hepatocyte invasion [33]. 
Sporozoite invasion of hepatocytes is initiated by the binding of parasite circumsporozoite protein 
(CSP) to heparin sulfate proteoglycans on the hepatocyte membrane, which activates parasite calcium-
dependent protein kinase 6 [34]. Binding of CSP to heparin sulfate proteoglycans triggers a cascade of 
events within the sporozoite resulting in the cleavage of CSP and the release of thrombospondin-related 
anonymous protein, and apical membrane antigen 1 from rhoptries and micronemes, which are secretory 
organelles unique to Apicomplexa [35]. Because CSP is necessary for hepatocyte invasion, both B-cell 
and T-cell epitopes of the protein are immunogenic targets of the RTS,S malaria vaccine [36,37]. 
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Once inside the hepatocyte, the sporozoite transforms into the liver-stage form and generates a 
parasitophorous vacuole membrane, an additional extracellular membrane that separates the parasite 
from the host cytoplasm, protects it from host immune responses, and allows it to regulate its metabolic 
micro-environment [38]. Liver-stage parasites then undergo schizogony over the course of one to two 
weeks to produce tens of thousands of merozoites. In most instances hepatocytes then release vesicles 
of merozoites called merosomes, beginning the asexual blood stage cycle of infection [39]. However, in 
P. ovale and P. vivax, a fraction of the sporozoites transition into dormant hypnozoites, which can 
reactivate after successful treatment of blood-stage infection to cause relapsing malaria.  
Each asexual blood stage cycle of P. falciparum malaria takes approximately 48 hours in P. 
falciparum and begins with the merozoite invasion of erythrocytes [31]. Merozoite invasion occurs in three 
stages over approximately two minutes: pre-invasion, active invasion, and echinocytosis [40]. Pre-
invasion likely begins with weak interactions between yet unknown erythrocyte membrane proteins and 
merozoite surface protein 1, which is found at high levels on the surface of merozoites [41]. While the 
precise nature of merozoite surface protein 1-erythrocyte interaction remains to be elucidated, it is 
hypothesized to occur through intermediate parasite proteins and is inhibited by heparin [40,42,43]. The 
next step of pre-invasion involves the strong interaction of erythrocyte binding-like proteins and P. 
falciparum reticulocyte-binding protein homologs with erythrocyte receptors including glycophorin A, B, C 
and complement receptor 1 [31]. Together, these pre-invasion interactions function to align the merozoite 
apical pole in the correct orientation for invasion, deforming the erythrocyte membrane, and signal the 
release of rhoptry proteins needed for active invasion. Active invasion begins with the interaction of the 
parasite P. falciparum reticulocyte-binding protein homologs 5 ligand with the erythrocyte receptor 
basigin, resulting in an influx of Ca2+ into the host cell [44,45]. This is followed by the formation of a 
moving junction between the merozoite and the erythrocyte consisting of rhoptry neck proteins deposited 
from the merozoite into the erythrocyte membrane, which are then bound by parasite apical membrane 
antigen 1 [46]. Once the moving junction is formed, parasite actomyosin motor proteins propel the 
merozoite into the erythrocyte, forming a parasitophorous vacuole membrane in the process [47]. Last, 
echinocytosis follows active invasion and is characterized by erythrocyte crenation, although the pointed 
membrane extensions subside as the host cell reestablishes osmotic equilibrium.  
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Following merozoite invasion, the asexual blood stage progresses through three stages: ring, 
trophozoite, and schizont. Ring stage parasites are characterized by slower metabolism and their ability 
to enter temporary dormancy in response to environmental stressors including decreased temperature, 
nutrient deprivation, or drug pressure [48]. Ring stage dormancy and recrudescence is implicated in the 
mechanism of resistance to artemisinins, the current first-line treatment for P. falciparum malaria [49]. 
During the trophozoite stage, metabolism increases and the parasite digests up to 75% of hemoglobin 
within the erythrocyte, it’s main source of energy and macromolecules [48]. Hemoglobin catabolism is 
accomplished by endocytosis of cytosomes of hemoglobin followed by fusion with the parasite’s digestive 
vacuole, which has an acidic environment (pH ~5.2) and contains numerous proteases including 
plasmepsins, falcipain, and faliclysin [50,51]. A consequence of hemoglobin catabolism is the production 
of the byproduct iron II protoporphyrin IX which is cytotoxic when oxidized to iron III protoporphyrin IX 
[52]. To counteract this toxicity, iron II protoporphyrin IX is detoxified by enzymatic crystallization into the 
inert brown pigment hemozoin, a process that is the target of the quinoline family of antimalarial drugs 
[53]. The final stage of the asexual blood stage is schizogony, where the parasite divides into 6-30 
merozoites before rupturing and beginning the cycle again [9]. Six to eight days after emerging from the 
liver and 12-14 days after an infectious bite, total body parasite burden can reach between 108-1012 
parasites [9].  
While most parasites in a P. falciparum infection progress through the asexual blood stage,  
between 0.1%-5% will differentiate into either male or female gametocytes that can be taken up by 
mosquitoes [54]. Once parasites are committed, gametocyte maturation takes 8-10 days and occurs in 
five phases, with forms that become increasingly oblong in shape [55]. In contrast to asexual blood stage 
parasites, immature gametocytes sequester in the bone marrow during development and there is 
evidence indicating that mature gametocytes migrate to subdermal capillaries to preferentially enhance 
uptake [56,57]. Gametocytogenesis is regulated by the highly-conserved apicomplexan transcription 
factor AP2-G, which in turn is epigenetically regulated by histone deacetylase 2 and heterochromatin 
protein 1 [58,59]. While the exact sequence of regulatory steps has yet to be determined, gametocyte 
production is influenced by environmental conditions faced by the parasite including high parasitemia, 
drug pressure, nutrient stress, anemia, and hemoglobinopathies [57].  
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After ingestion by a female Anopheles mosquito, mature P. falciparum gametocytes emerge from 
erythrocytes and develop into either male or female gametes in a process that is facilitated by decreased 
temperature, increased pH, and increased xanthurenic acid concentration [60,61]. This is followed by 
fertilization to produce diploid zygotes, which develop into ookinetes that migrate through the mosquito 
midgut and develop into oocysts. Finally, after oocysts mature for between 11-16 days, they release 
sporozoites that migrate to the mosquito salivary glands for onward transmission in the next blood meal 
[62]. Altogether, the time for one complete P. falciparum generation interval, including both human and 
mosquito phases, is as little as 43 days for an untreated infection [63]. 
1.3 Clinical characteristics and treatment  
Symptomatic P. falciparum infections are divided into two categories, uncomplicated and severe 
[30]. Symptoms of uncomplicated malaria are non-specific and include fever, chills, malaise, fatigue, 
diaphoresis, anorexia, nausea, vomiting, abdominal pain, diarrhea, arthralgias, and myalgias, headache, 
and cough [30,64]. The most prominent physical signs of uncomplicated malaria are manifestations of 
anemia (tachycardia, tachypnea, and pallor of the skin, mucous membranes, and sclera), hypotension, 
hepatomegaly, and splenomegaly. Although palpable splenomegaly may not be appreciated in adults 
who have experienced repeated episodes of malaria because of splenic shrinkage due to infarction. 
Clinical laboratory findings of uncomplicated malaria are anemia, thrombocytopenia, and elevated blood 
urea nitrogen, creatinine, and transaminases. Malaria-specific diagnostics are discussed in detail in 
Chapter 2, but the most common modalities for diagnosing P. falciparum malaria are microscopy 
combined with Giemsa-Wright staining and immunochromatographic rapid diagnostic tests (RDTs) for 
parasite histidine-rich protein 2 (HRP2) and lactate dehydrogenase (LDH) [65].  
The current standard of care for treating uncomplicated malaria is a three-day oral course of an 
artemisinin-based combination therapy (ACT) [65]. ACTs combine a fast-acting but short-lived artemisinin 
derivative that rapidly reduces parasite burden with a partner drug with a longer half-life to prevent 
recrudescence [66]. ACTs are highly effective in treating uncomplicated malaria, with successful 
treatment observed in over 98% of cases in sub-Saharan Africa [67]. When treated effectively before 
progressing to severe malaria, uncomplicated malaria has a mortality of approximately 0.1% [9]. 
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Severe malaria is characterized by the presence of one or more of the following signs or 
symptoms in the presence of a P. falciparum infection: coma, prostration, multiple convulsions within 24 
hours, acidosis, hypoglycemia, severe anemia, renal impairment, jaundice, pulmonary edema, significant 
bleeding, shock, or parasitemia >10% [65]. Of all the syndromes associated with severe malaria, coma 
and respiratory distress are the worst prognostic indicators and likely indicate cerebral malaria and acute 
respiratory distress syndrome, respectively [68]. Acidosis and renal impairment are additional predictors 
of mortality in the setting of severe malaria [69–71]. Children under 5 years are particularly vulnerable to 
developing severe malaria; in 2018, 67% (272,000) of all malaria deaths worldwide occurred in this age 
group [7].  
The current standard of care for treating severe malaria is intravenous artesunate for up to 7 days 
combined with supportive care in an intensive care setting [72]. Adjunctive therapies include mechanical 
ventilation, renal replacement therapy, fluid management, blood transfusion in the case of severe anemia, 
acetaminophen, and broad-spectrum antibiotics for bacterial co-infection with particular concern for non-
typhoid Salmonella [73–75]. While mortality from untreated severe malaria approaches 100%, it can be 
reduced to 10-20% depending on the time to treatment and level of available supportive care [65]. 
Beyond the mortality of severe malaria, up to 15% of children who survive cerebral malaria will have 
residual neurological sequelae of varying duration including hemiplegia, cerebral palsy, cortical blindness, 
deafness, cognitive and language deficits, increased incidence of epilepsy, and overall decreased life 
expectancy [76,77]. 
1.4 Pathogenesis and host responses 
The pathogenesis of severe malaria is ultimately caused by exponential parasite growth and 
results in end organ damage through a combination of host inflammatory responses, parasite 
cytoadherence and sequestration, endothelial dysfunction, and capillary obstruction [78]. In 
uncomplicated malaria, hosts typically develop symptoms once parasitemia increases above roughly 100 
parasites per microliter, although this varies with host immune status [30]. With exponential parasite 
growth increasing over ten-fold every 48 hours, parasitemia can rise into the tens of thousands per 
microliter in cases of severe malaria [9]. Parasites observed by microscopy represent an undercount due 
to cytoadherence of infected erythrocytes that have developed past the ring stage to capillary 
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endothelium, making measurements of parasite metabolites such as HRP2 a potentially more accurate 
method for estimating total body parasite burden [79].  
Cyclic, paroxysmal fevers have been recognized as characteristic of malaria since antiquity, even 
before Plasmodium parasites were identified as the causative agent [80–82]. In the 20th century, malarial 
fevers were briefly harnessed for medicinal purposes to treat neurosyphilis, earning Julius Wagner-
Jauregg the Nobel Prize in Physiology or Medicine in 1927 [83,84]. Malarial fevers are caused by the 
rupture of infected erythrocytes, which releases pathogen-associated molecular patterns including 
glycosylphosphatidylinositol and hemozoin [85,86]. These pathogen-associated molecular patterns are 
recognized by toll-like receptors on innate immune cells, which in turn release pyrogenic cytokines 
including tumor necrosis factor ⍺ and interleukin-10 [86–88]. In P. falciparum malaria, fevers are often 
asynchronous early in the course of disease before becoming synchronized at 48-hour intervals. While 
the precise mechanism of parasite synchronization is not yet known, there is evidence to support that it is 
an intrinsic molecular clock rather than a response to host cues [89].  
Cytoadherence and capillary sequestration of infected erythrocytes is fundamental to the 
pathogenesis of P. falciparum malaria and confers a survival advantage to parasites by allowing parasites 
to evade splenic filtration and immune clearance [90]. Cytoadherence is facilitated by P. falciparum 
erythrocyte membrane protein 1 (PfEMP1), which is synthesized by the parasite and exported to the 
erythrocyte surface [91]. There are approximately 60 different subtypes of PfEMP1 encoded by the var 
gene family, and only one of each subtype is expressed in a clonal line of parasites at a time [92]. 
PfEMP1 variants bind different endothelial receptors including intercellular adhesion molecule 1, 
endothelial protein C receptor, chondroitin sulphate A (CSA), and CD36 [91]. Parasites expressing 
PfEMP1 variants that bind different endothelial receptors are associated with different malarial 
pathologies; for example, parasites expressing PfEMP1 variants that bind intercellular adhesion molecule 
1 and endothelial protein C receptor are associated with cerebral malaria [93,94]. Similarly, CSA is 
expressed in the placenta, and parasites expressing the PfEMP1 variant VAR2CSA are associated with 
placental malaria [95].  
Sequestration of infected erythrocytes in severe malaria is followed by endothelial dysfunction, 
coagulopathy, and capillary obstruction [31]. Levels of nitric oxide and it’s precursor L-arginine are 
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depleted while dimethylarginine (a nitric oxide synthase inhibitor) is increased in patients with severe 
malaria, resulting in impairment of hypoxic signaling and vasodilation [96–98]. Endothelial dysfunction 
also increases expression of several receptors that PfEMP1 variants can bind, creating a negative 
feedback loop [31]. This cycle begins when infected erythrocytes bind and inhibit endothelial protein C 
receptor, which normally activates protein C [93]. Under normal conditions, protein C inhibits coagulation 
by cleaving and inactivating Factors Va and VIIIa, and protein C inhibition in turn leads to local 
hypercoagulation and endothelial dysfunction [99]. Local endothelial activation causes release of pro-
coagulation macromolecules including von Willebrand factor, which in turn bind activated platelets 
[100,101]. Activated platelets express CD36 which binds PfEMP1, recruiting additional infected 
erythrocytes through a process known as platelet-mediated agglutination [102,103]. Additionally, in 
severe malaria, uninfected erythrocytes become less deformable and can bind to infected erythrocytes in 
a process known as rosetting [90,104,105]. The end result of this cascade is capillary obstruction and 
impaired blood flow and ischemia to affected organs including the brain (cerebral malaria), lungs (acute 
respiratory distress syndrome), and kidneys (renal failure) [106].  
Severe anemia is another mechanism of pathogenesis in severe malaria and can have multiple 
etiologies [107]. A high background level of iron deficiency anemia is common in regions where malaria is 
endemic; interestingly, iron deficiency anemia has been shown to be protective against malaria [108,109]. 
Dyserythropoiesis is also observed in severe malaria and is hypothesized to be caused by hemozoin 
deposition and high levels of proinflammatory cytokines produced during acute illness [110]. Direct lysis 
of infected erythrocytes during schizont rupture contributes to anemia as well, as does the intravascular 
hemolysis of uninfected erythrocytes brought on by decreased deformability and erythrocyte 
sequestration due to rosetting [105]. Last, splenic filtration and clearance of both infected and uninfected 
erythrocytes is increased during acute malaria, further decreasing the amount of erythrocytes in 
circulation [111,112]. 
Beyond stimulating an innate inflammatory response, repeated episodes of malaria cause the 
adaptive immune system to produce antibodies against sporozoite, merozoite, and erythrocyte cell-
surface antigens [113]. Peptides expressed in these stages are exposed to immune surveillance, while 
the rest of the parasite's life cycle is completed inside the relatively hidden parasitophorous vacuole. 
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Antibodies against sporozoite stage proteins CSP, thrombospondin-related anonymous protein, and liver-
stage antigen 1 have been found in subjects from malaria-endemic regions and are associated with lower 
incidence of disease [114–117]. Naturally-acquired anti-sporozoite antibodies do not appear to be long-
lasting and sufficient for complete sterilizing immunity, potentially due to the relatively low antigen 
exposure of an infectious bite [118–121]. The RTS,S malaria vaccine seeks to overcome this barrier by 
introducing the immune system to a much higher quantity of antigen in the form of a CS-hepatitis B 
surface antigen fusion protein, which is co-expressed in yeast with hepatitis B surface antigen alone to 
form immunogenic particles [36,37]. While the RTS,S vaccine is somewhat effective - a Phase III clinical 
trial in over 15,000 children showed reductions in malaria incidence of 28% in young children and 18% in 
infants - it offers relatively short-lived protection and requires 3-4 doses over 48 months [122].  
In the asexual blood stage, merozoite surface protein 1 and apical membrane antigen 1 and 
PfEMP1 are immunogenic, and antibodies against these proteins are detectable in adults in malaria-
endemic regions [113]. However, efforts to develop broadly-effective vaccines or monoclonal antibodies 
targeting these proteins have been disappointing, with the exception of a vaccine targeting the PfEMP1 
variant VAR2CSA (discussed in the following section). This is likely due to the large amount of antigenic 
variation in each of these loci, such that an infection by parasites possessing one combination of these 
proteins does not confer immunity against parasites possessing a different combination of proteins. This 
is in accordance with the observation that immunity to malaria is partial and age-dependent; it increases 
with successive exposures to antigenically varied parasites over a lifetime [123]. The clinical 
consequences of this life cycle of immune development are that young children (especially <5 years) are 
the most susceptible to severe malaria, while adolescents and young adults are more likely to present 
with uncomplicated malaria, and older adults in malaria-endemic regions develop asymptomatic 
parasitemia. One consequence of improved malaria control efforts is that with fewer cases in younger 
children, the burden of severe disease may shift to older children and adults [31]. 
1.5 Malaria in pregnancy 
Over 125 million women each year are at risk for malaria in pregnancy including nearly all 
pregnant women in the DRC, which is a significant source of morbidity and mortality to both mothers and 
their children [124,125]. While the burden of malaria in pregnancy is difficult to state precisely, it is 
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estimated to cause up to 20% of maternal mortality and 30,000 deaths annually in malaria-endemic 
countries, often through the compounding syndromes of severe anemia, postpartum hemorrhage, and 
sepsis [73,124,126]. The risk of developing severe malaria, which has a mortality of up to 50% in 
pregnant women, is highest in areas of low transmission and thus low levels of pre-existing partial 
immunity [65,127,128]. Beyond maternal risk, malaria is associated with a 3-4 times increased risk of 
miscarriage and accounts for up to 20% of stillbirths in sub-Saharan Africa, totaling 200,000 annually 
[8,129,130]. Malaria in pregnancy is more insidious in areas of high transmission, and births are often 
complicated by low birth weight (either due to preterm birth or intrauterine growth restriction), 
susceptibility to other infectious diseases, and other long-term complications that are estimated to 
indirectly cause an additional 100,000 infant deaths annually in Africa alone [131].   
The pathogenesis of malaria in pregnancy is mediated by the PfEMP1 variant VAR2CSA, which 
binds the glycosaminoglycan chondroitin sulfate A present in the intervillous space of the placenta 
[132,133]. Parasite sequestration in the placenta is followed by monocyte infiltration and inflammatory 
cytokine release, which in turn causes impaired placental angiogenesis, reduced nutrient transport and 
ultimately disruption of fetal growth [134]. These effects are most severe in primigravid women; with 
multiple pregnancies, women develop antibodies to VAR2CSA that are protective against negative birth 
outcomes associated with malaria in pregnancy [95,135,136]. For this reason, VAR2CSA is a promising 
antigenic target for vaccines to prevent malaria in pregnancy, and two clinical trials based on this premise 
are currently in progress (PRIMVAC and PAMVAC, ClinicalTrials.gov Identifiers NCT02658253 and 
NCT02647489, respectively). While Phase I results indicate that both vaccines are well-tolerated and 
immunogenic against specific VAR2CSA variants, there is evidence for diminished cross-reactivity of the 
immune response against heterologous VAR2CSA variants that may necessitate the use of a multi-
antigen combination approach to provide immunity against diverse parasite populations [137–140]. 
1.6 Chemoprophylaxis of malaria  
It has been said that “An ounce of prevention is worth a pound of cure”, and this maxim holds true 
for public health approaches to malaria control [141]. Alongside insecticide-treated bed nets, indoor 
residual spraying, environmental modifications to reduce mosquito breeding grounds, and improved 
housing, chemoprophylaxis is an important part of malaria prevention worldwide [7]. Malaria 
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chemoprophylaxis in sub-Saharan Africa takes three main forms; seasonal malaria chemoprophylaxis, 
intermittent preventive treatment in infants (IPTi), and intermittent preventive treatment in pregnancy 
(IPTp) [7]. In the Sahel region of sub-Saharan Africa where malaria transmission is relatively low and 
seasonal, the WHO recommends seasonal malaria chemoprophylaxis for children between 3 and 59 
months of age [142]. The current recommended antimalarial combination for seasonal malaria 
chemoprophylaxis is a full course of amodiaquine combined with sulfadoxine-pyrimethamine (SP) divided 
into four doses throughout the malaria transmission season and when administered correctly, seasonal 
malaria chemoprophylaxis can prevent up to 75% of all uncomplicated and severe malaria and reduce 
child mortality by up to 0.1% [142]. In regions of sub-Saharan Africa with moderate-to-high malaria 
transmission (annual entomological inoculation rate ≥ 10, nearly the entire DRC), the strategy for malaria 
chemoprophylaxis shifts to IPTi, which emphasizes preventing malaria in the first year of life when infants 
are at highest risk of mortality [143]. IPTi is often paired with preventative health schedules like 
pentavalent vaccines (a 5-1 vaccination against diphtheria, pertussis, tetanus, hepatitis, B and 
Haemophilus influenzae type b) such that a full course of SP is given at 8-10 weeks, 12-14 weeks, and 9 
months of age [144]. In the first year of life, IPTi with SP reduces the incidence of uncomplicated malaria 
by 30%, anemia by 21%, malaria-associated hospitalization by 38% and all-cause hospitalization by 23% 
for infants in moderate-to-high transmission settings [144].  
To prevent malaria in pregnancy, the WHO currently recommends IPTp with up to six doses of 
SP at least one month apart, beginning in the second trimester of pregnancy [145]. In meta-analyses of 
interventional trials in moderate-to-high transmission settings, IPTp is associated with a 27% risk of low 
birth weight and a 21% reduction in perinatal mortality [146,147]. Beyond reducing infant morbidity and 
mortality, IPTp reduces the risk of moderate or severe anemia in primigravid and secundigravid mothers 
by up to 40% [148]. The benefits of IPTp are substantial when modeled across sub-Saharan Africa; it is 
estimated that without pregnancy-specific interactions (including IPTp and insecticide-treated bed nets), 
an additional 900,000 low birth weight deliveries would occur annually in sub-Saharan Africa [149]. 
Despite these clear benefits, in 2018 only 60% of women received at least one dose of IPT-p SP in sub-
Saharan Africa, with only 31% of women (approximately 50% in the DRC) receiving at least three [7]. 
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1.7 Sulfadoxine-pyrimethamine and antifolate resistance 
Antimalarial drugs targeting the folate synthesis pathway are commonly used for malaria 
chemoprophylaxis in sub-Saharan Africa [145]. The final product of the folate synthesis pathway is 
tetrahydrofolate, which functions as a cofactor for single carbon transfer reactions in nucleic acid and 
amino acid synthesis pathways [150]. While most multicellular eukaryotes other than plants cannot 
synthesize their own folate, the unicellular P. falciparum can synthesize its own folate from GTP, p-
aminobenzoate, and glutamate [151–154]. Although P. falciparum is also capable of utilizing host-derived 
folate, parasite folate synthesis is an essential pathway and its inhibition is lethal [155]. Antimalarial drugs 
that act on the folate synthesis pathway are synergistic competitive inhibitors; sulfadoxine and dapsone 
inhibit dihydropteroate synthetase (dhps), while pyrimethamine and proguanil inhibit dihydrofolate 
reductase (dhfr) [150,156]. Because of their synergistic effects, antimalarial drugs that inhibit the folate 
synthesis pathway are always given in combination and are often discussed together as a single 
therapeutic option that itself can be combined with other antimalarial drugs (such as artesunate) [157].  
As is common with the vast majority of antimalarial drugs, P. falciparum has evolved antifolate 
resistance in the form of point mutations in dhps and dhps [158–160]. Antifolate resistance typically 
evolves in a progressive manner, with each step leading on an increasingly resistant phenotype 
[157,161]. The first variant observed is usually dhfr 108N/T, which confers a nearly 100-fold increase in 
pyrimethamine resistance in vitro [162,163]. Additional dhfr variants including 51I, 59R, and 164L can 
confer an additional ten-fold resistance on a 108N background [164–167]. Variants in dhps evolve in a 
similar manner, with 437G emerging first and then followed by combinations of 436A/F, 540E, 581G, and 
613S/T [168–171]. Through successive generations of mutation, recombination, and selection, different 
haplotypes of these alleles have emerged and spread, each conferring more SP resistance than its 
predecessor [172]. The most commonly observed haplotypes are often referred to as “triple mutant” (dhfr 
51I, 59R, 108N), “quadruple mutant” (+dhps 437G), “quintuple mutant” (+dhps 540E) and or “sextuple 
mutant” (+dhps 581G) [172]. 
The clinical consequences of antifolate resistance increase with each variant present in an SP-
resistant haplotype. The presence of dhfr 108N alone or in combination with 59R is not sufficient to cause 
clinical treatment failure for uncomplicated malaria with SP; treatment failure begins with triple mutant 
14 
haplotypes and high levels of failure are observed with quintuple mutant haplotypes [173–176]. Despite 
its limited efficacy in treating highly-resistant cases of uncomplicated malaria, SP remains effective for 
IPTp even when quintuple mutant haplotype prevalence is >90%, although SP IPTi is not recommended 
when quintuple mutant haplotype prevalence is ≥50% [143,147,177]. Of particular concern, SP IPTp loses 
its protective effects against low birth weight in regions where the sextuple mutant haplotype prevalence 
is >10% [147,178].  
Evidence of the potential for parasites to develop antifolate resistance were available as early as 
the 1950’s, and concerns about resistance increased as antifolate use became more widespread 
beginning with South America and Southeast Asia in the 1970’s [160,161]. In the 1990’s, SP became the 
first-line antimalarial drug in many sub-Saharan African countries that were facing widespread treatment 
failure from parasite resistance to the previous first-line agent, chloroquine [157,179,180]. During this 
period, the triple mutant haplotype reached fixation throughout Southeast Asia, spread to sub-Saharan 
Africa, and accumulated additional dhps variants, rendering SP no longer suitable for treating 
uncomplicated  malaria [181,182]. The spread of SP resistance throughout sub-Saharan Africa prompted 
serious concerns for a future without effective first-line antimalarial drugs and severe increases in 
morbidity and mortality [157]. Thankfully, this concern was somewhat alleviated when ACTs became the 
first-line treatments for uncomplicated and severe malaria beginning in 2003-2008 [183]. However, 
because SP remains in use for malaria chemoprophylaxis in sub-Saharan Africa, the spread of high-level 
antifolate resistance remains a major issue, especially in countries with a high malaria burden like the 
DRC. 
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CHAPTER 2: A NOVEL CRISPR-BASED MALARIA DIAGNOSTIC CAPABLE OF PLASMODIUM 
DETECTION, SPECIES DIFFERENTIATION, AND DRUG-RESISTANCE GENOTYPING1 
2.1 Introduction 
2.1.1 Malaria diagnostics 
Timely and accurate diagnosis is essential for the treatment of malaria. Beyond the clinic, 
detecting Plasmodium parasites is an important aspect of malaria surveillance and control programs. In 
settings where malaria is most prevalent, the most common diagnostics to detect malaria are light 
microscopy and antigen-based RDTs. In the last decade, significant progress has been made in 
expanding access to malaria diagnostics worldwide; of patients who presented to public health facilities 
and were suspected of having malaria, the percentage who were tested with either a RDT or microscopy 
increased from 38% in 2010 to 85% in 2018 [7].  
 Light microscopy is the gold standard for malaria diagnosis; in this process, a drop of blood is 
smeared across a microscope slide, stained with either Field’s or Giemsa stain, and fixed with methanol 
whereupon basophilic Plasmodium parasites can be visualized within eosinophilic erythrocytes. Thick 
blood films facilitate sensitive parasite detection, and thin blood films allow species differentiation and 
quantification [30]. Light microscopy has several advantages for malaria diagnosis. The lower limit of 
detection for thick film microscopy is between 11-50 parasites/µL, which is below parasitemias typically 
seen in uncomplicated malaria [184]. Accordingly, clinical sensitivity and specificity for malaria diagnosis 
with light microscopy are both typically greater than 90% for a trained microscopist [185].  
One advantage of light microscopy is that it is inexpensive (estimated $0.37-$1.27 per test) 
compared with existing molecular diagnostic methods and can be field-friendly in countries where malaria 
                                                     
1 This chapter originally appeared as an article that was accepted by the journal EBioMedicine on May 12, 2021. 
Manuscript number EBIOM-D-20-02847R2. The original citation is as follows: Cunningham CH, Hennelly CM, Lin JT, 
Ubalee R, Boyce RM, Mulogo EM, Hathaway N, Thwai KL, Phanzu F, Kalonji A, Mwandagalirwa K, Tshefu A, Juliano 
JJ, Parr, JB. “A novel CRISPR-based malaria diagnostic capable of Plasmodium detection, species differentiation, 
and drug-resistance genotyping,” EBioMedicine (May, 2021) 
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is most prevalent [186]. Additionally, light microscopy can provide quantitative data on parasitemia, which 
can be used to determine hyperparasitemia in severe malaria and monitor parasite clearance during a 
treatment course. One of the main disadvantages of light microscopy is that it requires significant training 
and expertise to achieve optimal performance which can result in inter-user variability and poor 
performance with inexperienced or overburdened microscopists [185]. Other disadvantages include that 
slide staining and processing is labor-intensive, and microscopes can be expensive and require stable 
electricity and regular maintenance.  
In settings where microscopy may be impractical or unavailable, RDTs are a mainstay in malaria 
diagnosis. In 2018, an estimated 412 million RDTs were sold worldwide. These RDTs were used over 
three times as frequently as microscopy to diagnose malaria in sub-Saharan Africa [7]. RDTs are 
immunohistochemical assays that use antibody-binding interactions to detect the presence of parasite 
antigen in a blood sample [187]. To operate an RDT, a small sample of blood is collected from a finger or 
heel prick and placed on a lateral flow strip with a running buffer, which causes the sample to migrate by 
capillary action [187]. A line of membrane-bound antibodies then captures parasite antigen in the sample, 
which are in turn bound by free dye-labeled antibodies to produce a colorimetric readout that can be 
visualized with the naked eye. The most common RDTs target P. falciparum-specific HRP2, but other 
pan-Plasmodium antigen targets include LDH and aldolase [72]. The lower limit of detection of the most 
common RDTs is approximately 200 parasites/µL, while novel ultrasensitive RDTs can detect as low as 2 
parasites/µL [72,188]. RDTs are a highly effective clinical diagnostic; in a meta-analysis of the most 
common malaria RDTs including 74 independent studies of patients with symptomatic malaria, RDTs 
antigen-based RDTs averaged over 90% sensitivity and specificity [189] The most common HRP2-based 
RDTs averaged 94.8% sensitivity and 95.2% specificity, which was slightly more sensitive and less 
specific compared with LDH-based RDTs at 91.5% sensitivity and 98.7% specificity.  
As their name suggests, a major advantage of RDTs is that they provide rapid results, typically in 
under 15 minutes [190]. RDTs are also easy to conduct in a few simple steps, so they can be performed 
by clinical or field workers with little formal training. They are also one of the least expensive malaria 
diagnostics averaging between $0.60-$1.00 per test and have no required instruments, which is essential 
given that malaria is most prevalent in low and middle income countries [186]. These compelling 
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advantages have led to the widespread uptake of RDTs as point-of-care tests, making them the 
benchmark to beat for other field-friendly malaria diagnostics. Disadvantages of RDTs include that they 
are not quantitative and cannot be used to monitor parasitemia during treatment because parasite 
antigens persist in the blood for up to a month after clearance [72]. RDTs are also sensitive to the high 
heat and humidity common in malaria-endemic regions and have a shelf-life of 6-18 months that can 
make it difficult to maintain a constant supply in remote areas [191,192]. RDTs demonstrate reduced 
sensitivity and specificity compared with light microscopy for detecting asymptomatic malaria, which is an 
important consideration for malaria surveillance and control programs [193,194].  
Last and most concerning, there is a growing body of literature describing strains of P. falciparum 
with deletions in pfhrp2 as well as pfhrp3, which cross-reacts with the antibodies on HRP2-based RDTs 
[195]. First reported in field samples from Peru in 2010, parasites with pfhrp2 and/or pfhrp3 (pfhrp2/3) 
deletions have now been observed throughout South and Central America, India, and sub-Saharan Africa 
[196]. Infection with parasites possessing pfhrp2/3 deletions is characterized by a negative HRP2-based 
RDT but positive microscopy and confirmed by pfhrp2/3-specific polymerase chain reaction (PCR) to rule 
out RDT performance as the cause of the negative result [195]. Pfhrp2/3 deletions are a major 
vulnerability for HRP2-based RDTs as they would render the parasites “RDT-resistant” and cause 
incorrect clinical diagnosis and treatment. While pfhrp2/3-deleted parasites account for a relatively small 
proportion of parasites in most locations, recent evidence from the Horn of Africa suggests that pfhrp2/3-
deleted parasites are compromising clinical care. Selection of these parasites could compromise RDT 
efficacy and cause a resurgence of malaria cases and deaths in sub-Saharan Africa.  
2.1.2 Molecular diagnostics for malaria 
To address some of the shortcomings of microscopy and RDTs for malaria diagnosis and 
surveillance, nucleic acid-based molecular diagnostics have been developed. One such method is PCR, 
a technique that amplifies DNA (deoxyribonucleic acid) using a thermostable DNA polymerase, synthetic 
oligonucleotide primers, and repeated cycles of heating and cooling in a thermal cycler instrument [197]. 
PCR was subsequently optimized for the detection of quantification of low concentrations of DNA through 
quantitative PCR (qPCR), which uses intercalating fluorescent dye or fluorophore/quencher interactions 
to generate fluorescent output proportional to the amount of DNA amplicon produced [198–200]. Both 
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pan-Plasmodium and species-specific qPCR assays have been developed; the most common gene 
target of these assays is the small subunit 18S ribosomal ribonucleic acid (rRNA) gene, which is present 
in between 4-8 copies per parasite and contains constant regions for primer binding and variable regions 
for probe targeting [201,202]. The lower limit of detection for qPCR is between 1-10 parasites/µL, 
although ultrasensitive PCR, quantitative reverse-transcription PCR, and digital-droplet PCR methods can 
detect 50-100-fold less DNA down to 22, 20, and 11 parasites/mL, respectively [203–205]. The clinical 
performance of qPCR for malaria diagnosis is excellent; in a meta-analysis of 4,974 symptomatic malaria 
patients across 17 studies, qPCR was 100% sensitive and 93% specific compared with microscopy 
[206].  
One of the primary advantages of qPCR as a malaria diagnostic is its low limit of detection, giving 
it the ability to detect submicroscopic early-stage and asymptomatic infections [185]. The ability to 
quantify parasites and differentiate Plasmodium species are also assets of qPCR, as is the ability to 
process samples in 96 or 384-well plates. Beyond detection, quantification, and species differentiation, 
qPCR can also distinguish between single nucleotide variants (SNVs) using allele-specific probes, 
including for the dhps variant 581G associated with high-level sulfadoxine resistance [207]. The single 
nucleotide granularity of qPCR is qualitatively different from what can be observed using RDTs and 
microscopy and has uses beyond clinical diagnosis into research and drug resistance surveillance. 
However, there are significant drawbacks of qPCR that prevent it from overtaking all other malaria 
diagnostics in all settings. Thermal cyclers capable of running qPCR are expensive, as are the reagents 
and laboratory infrastructure necessary to carry out the assay at scale. qPCR reactions take several 
hours from start to finish, which is a major disadvantage in a clinical setting compared with point-of-care 
RDTs. Because hemoglobin inhibits most thermostable polymerases, qPCR assays typically require a 
DNA extraction step that adds additional time, complexity and cost, although direct blood PCR methods 
exist to help circumvent this requirement [208–210]. Last, qPCR is a technically challenging assay and 
requires extensive training and knowledge of molecular biology to conduct and troubleshoot that may not 
be available in low-resource settings. 
Loop-mediated isothermal amplification (LAMP) is another molecular diagnostic used to detect 
malaria and possesses a slightly different profile of strengths and weaknesses compared with qPCR, 
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microscopy, and RDTs. LAMP uses a thermostable polymerase with DNA helicase activity and four 
primers that recognize six binding sites to amplify DNA by strand displacement synthesis at a constant 
temperature of 65°C [211]. The products of LAMP are not identical amplicons like in PCR but a series of 
concatenated double-stranded DNA (dsDNA) stem-loops that can be detected by turbidity, colorimetry, 
fluorescence, or lateral flow [212–214]. LAMP has been adopted to malaria in both pan-Plasmodium and 
species-specific assays, with lower limits of detection of between 2.5-0.25 parasites/µL [215–218]. 
Clinically, LAMP is nearly as sensitive and specific as microscopy for malaria diagnosis; in a meta-
analysis of 1,449 symptomatic malaria patients across 6 studies, LAMP was 98% sensitive and 97% 
specific [206]. Compared with PCR, LAMP has similar sensitivity but slightly lower specificity; in a meta-
analysis of 604 symptomatic malaria patients across 9 studies, LAMP was 98% sensitive and 93% 
specific [206].  
Many of the advantages of LAMP as a diagnostic are similar to qPCR; low limit of detection, 
excellent clinical sensitivity although slightly lower specificity, and ability to differentiate between 
Plasmodium species. LAMP can also be designed to distinguish between SNVs, including variants 
associated with artemisinin and pyrimethamine resistance in P. falciparum [219–221]. In contrast to 
qPCR, LAMP can be completed in under an hour and utilizes less expensive instruments compared with 
thermal cyclers. LAMP is also more streamlined than qPCR in that it can use supernatant from blood that 
has been heat-treated and centrifuged as a sample rather than extracted DNA [217]. Despite these 
advantages, LAMP still falls short as a point-of-care test; compared with RDTs it remains slower, more 
expensive, and requires more laboratory infrastructure and molecular biology expertise to design, 
operate, and troubleshoot assays.  
2.1.3 CRISPR-based diagnostics 
In recent years, a suite of novel molecular diagnostics has been developed using techniques 
derived from clustered regularly-interspaced short palindromic repeats (CRISPR) and CRISPR-
associated systems (Cas). The sequences that would later be called CRISPRs - genomic regions of 29 
nucleotide “repeats" interspaced with variable 32 nucleotide “spacers” - were discovered in Escherichia 
coli in 1987 [222]. Over the next two decades, the function of CRISPR sequences and Cas proteins was 
elucidated: an adaptive immune system that protects prokaryotes against bacteriophage or plasmid 
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infection through targeted degradation of foreign nucleic acid [223,224]. The CRISPR/Cas immune 
system begins with the detection, processing, and insertion of foreign nucleic acid by a Cas1-Cas2 
complex to form the spacers of a CRISPR locus [225]. CRISPRs are then transcribed, processed, and 
base-paired with an additional trans-activating CRISPR RNA to form CRISPR RNAs (crRNAs) [226]. 
Mature crRNAs are composed of a spacer that is complementary to a foreign nucleic acid sequence and 
a repeat that base-pairs with the trans-activating CRISPR RNA and associates with Cas endonucleases 
to form a ribonucleoprotein complex [227]. Cas endonucleases are activated by the highly specific 
Watson-Crick base-pairing of the crRNA spacer with the complementary foreign nucleic acid, resulting in 
the cleavage of the foreign nucleic acid at a prescribed site [228]. The role of CRISPR/Cas systems as a 
prokaryotic adaptive immune system was demonstrated through a series of experiments in Streptococcus 
thermophilus showing that bacteria integrate new spacers into their genome after foreign exposure and 
that modification of these spacers affects foreign resistance [229].  
While CRISPR/Cas systems may have evolved as a prokaryotic immune system, they are best 
known for their role in revolutionizing genome editing. Generating dsDNA breaks is an essential 
prerequisite in genome editing as they enable subsequent repair by non-homologous end joining to 
create frame-shift knockouts or homology-directed repair to create targeted insertions, deletions, or single 
nucleotide changes [230]. Before CRISPR/Cas, the most efficient method of generating targeted dsDNA 
breaks for genome editing was to use zinc-finger nucleases and transcription activator-like effector 
nucleases, which recognize dsDNA targets through nucleic acid-amino acid motif interactions [230]. 
However, changing the target sequence required changing the primary structure of the zinc finger 
nucleases and transcription activator-like effector nucleases, which in turn required laborious and 
expensive protein engineering. Genome editing with Cas9, a crRNA-guided DNAse, solves this problem 
by facilitating easy double strand break targeting: changing the spacer region of the associated crRNA 
requires only a simple commercial oligonucleotide synthesis [231]. It is difficult to overstate the impact of 
CRISPR/Cas9 genome editing has had on biomedical science in the last decade; It has enabled precise 
knock-in studies to characterize gene function, facilitated massively multiplexed knock-out screens to 
study complex pathways, heralded promising gene therapies for monoallelic diseases, and earned a 
Nobel Prize in Chemistry for Emmanuelle Charpentier and Jennifer Doudna in 2020 [232–236]. 
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While lesser known compared with Cas9, CRISPR associated endonucleases Cas12a and 
Cas13a have the potential to revolutionize molecular diagnostics [237,238]. Both endonucleases behave 
similarly to Cas9 in that they bind specific crRNAs that associate with target nucleic acids by Watson-
Crick base pairing, although Cas12a is a single-stranded DNAse and Cas13a is a single-stranded 
RNAse. What makes these endonucleases unique is that after cleaving a crRNA-targeted nucleic acid, 
they become activated and exhibit collateral, non-specific nuclease activity, degrading any other ssDNAs 
or ssRNAs present [239,240]. The utility of this off-target nuclease activity in the context of a prokaryotic 
immune system is presently unclear, though it has been shown to slow bacterial growth in vitro and may 
be part of a dormancy-inducing or cellular suicide mechanism [238,241]. The sequence of highly specific 
crRNA binding causing off-target nuclease activity that can be detected by fluorescence, colorimetry, or 
lateral flow is the fundamental underlying principle of CRISPR-based diagnostics [239,240] 
Specific, high-sensitivity enzymatic reporter unlocking (SHERLOCK) is a CRISPR-based 
diagnostic that combines recombinase polymerase amplification (RPA), in vitro transcription, and RNA 
target detection using custom-designed crRNA oligonucleotides and Cas13a derived from the bacteria 
Leptotrichia wadei (LwCas13a) (Figure 2.1) [240]. The first step of SHERLOCK is an RPA reaction 
performed with primers tagged with a T7 promoter sequence to generate short dsDNA amplicons of a 
target sequence. In vitro transcription of the RPA product by T7 polymerase produces single-stranded 
RNA (ssRNA) targets, which are recognized by base-pairing interactions with LwCas13a:crRNA complex. 
CrRNA-ssRNA target base-pairing interactions activate collateral ribonuclease (RNAse) activity of 
LwCas13a, which cleaves fluorescent or colorimetric RNA reporter molecules in the reaction to produce a 
detectable signal. SHERLOCK can also detect SNVs; crRNA-ssRNA target base-pairing interactions are 
perturbed by mismatches in the target region, leading to differential LwCas13a activation depending on 
the presence or absence of a variant (Figure 2.2). Reaction components can be combined into either one 
or two reactions, with detection on a simple fluorimeter, lateral flow strip, or gold nanoparticle-based 
colorimetry [242,243]. The range of potential applications for SHERLOCK is broad; reported applications 
include distinguishing Zika and dengue virus strains, genotyping human cancers and transgenic rice, 
detecting antimicrobial resistance SNVs, and detecting several agricultural viruses as well as the SARS-
CoV-2 coronavirus [240,242–246]. 
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Here, we describe novel proof-of-concept SHERLOCK assays that enable robust detection of five 
Plasmodium species known to be pathogenic to humans and species-specific detection of the primary 
causes of human disease P. falciparum and P. vivax. We apply these assays to a panel of laboratory 
parasite strains, diverse clinical isolates from Africa and Asia, and pools of Anopheles mosquitoes 
collected in the field. We then describe an assay for detection of the 581G SNV in the P. falciparum dhps 
gene associated with resistance to sulfadoxine-pyrimethamine, the primary antimalarial medication used 
in IPTp throughout Africa [247]. While further optimization and streamlining is necessary before these 
assays can be used clinically, we demonstrate the potential of SHERLOCK-based diagnostics for the 
detection of malaria and other human pathogens.  
2.2 Materials and Methods 
2.2.1 RPA primer design 
We designed RPA primers capable of genus-specific amplification of the Plasmodium 18S 
ribosomal RNA gene, building upon existing TaqMan real-time PCR assays [201]. PCR primers were 
extended to 30-35 nt in length and modified to include nucleotide favorability criteria described in the 
TwistAmp Assay Design Manual [248]. These RPA primers target regions of the 18S rRNA gene that are 
conserved across human-infecting Plasmodium species, allowing “plug and play” crRNA design for 
species identification during the crRNA:LwCas13a base-pairing step of SHERLOCK. RPA primers for the 
dhps SNV-detection SHERLOCK assays were designed using NCBI Primer Basic Local Alignment 
Search Tool with default parameters and the following modifications: amplicon size 100-140 nt, melting 
temperatures between 54-67°C, and length between 30 and 35 nucleotides [249]. We then added a T7 
promoter sequence (5’-GAAATTAATACGACTCACTATAGGG-3’) to the 5’ end of one RPA primer in each 
set to enable in vitro transcription by T7 polymerase during the LwCas13a detection step. All primers with 
off-target complementarity predicted by Basic Local Alignment Search Tool were excluded. Salt-free 
primers were synthesized by Integrated DNA Technologies (Coralville, Indiana). The full list of 
oligonucleotides designed and used in this chapter can be found in Table 2.1. 
2.2.2 crRNA design 
Oligonucleotides for crRNA synthesis were designed as two complementary ssDNA 
oligonucleotides and then in vitro transcribed to produce single-stranded 67 nt crRNAs. Each ssDNA 
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oligonucleotide was composed of three parts: a variable spacer region (to facilitate recognition of the RNA 
target molecule), a constant region (to facilitate crRNA association with LwCas13a), and a T7 promoter 
sequence (to facilitate crRNA in vitro transcription). Spacers are 28 nt long and recognize the in vitro 
transcribed RNA product of the RPA reaction through complementary base-pairing [240]. For the P. 
falciparum and P. vivax species-specific SHERLOCK assays, spacers were designed to bind a species-
specific region of the 18S rRNA gene previously targeted for amplification during real-time PCR assays 
[201]. Spacers were selected to have at least three mismatches between species for the P. falciparum 
and P. vivax-specific assays to minimize off-target activity. For the pan-Plasmodium SHERLOCK assay, a 
spacer was selected in a region of the 18S rRNA gene conserved between Plasmodium species. 
Spacers for dhps SHERLOCK assays were designed to maximize the difference in signal 
between a specific SNV and alternate motifs as previously described [240]. To accomplish this, spacers 
were designed so the SNV is recognized at position 3 or 6, and a synthetic mismatch between the spacer 
and target was present at position 5 or 4, respectively (Table 2.2). The resulting spacer has one 
mismatch with the SNV of interest and two mismatches with the alternate variant, producing a 
measurable difference in signal between the two variants (Figure 2.2). Spacers were queried through 
Basic Local Alignment Search Tool to search for any off-target complementarity [249]. 
The same constant LwCas13a-associating region was used as described in Gootenberg et al. 
(2017), 5’-GGGGAUUUAGACUACCCCAAAAACGAAGGGGACUAAAAC-3’, and the T7 promoter 
sequence used was 5’-GAAATTAATACGACTCACTATAGGG-3’ [240]. Put together, two 89 nt ssDNA 
oligonucleotides (appended to spacer sequences) for each crRNA were designed in the format 5’-
GAAATTAATACGACTCACTATAGGGGATTTAGACTACCCCAAAAACGAAGGGGACTAAAAC-spacer-3’ 
and 5’-spacer reverse complement-
GTTTTAGTCCCCTTCGTTTTTGGGGTAGTCTAAATCCCCTATAGTGAGTCGTATTAATTTC-3’. These 
oligonucleotides were ordered from Integrated DNA Technologies (Coralville, IA). For each SHERLOCK 
assay, multiple crRNA designs were screened, and crRNAs with the greatest signal:background and/or 
SNV signal:alternate signal were selected for all future experiments (Figures 2.3-2.5). 
24 
2.2.3 crRNA synthesis 
Complementary ssDNA oligonucleotides were annealed (final concentration 10 µM each) in 10 
mM Tris‐HCl, 50 mM KCl, and 1.5 mM MgCl2 pH 8.3 for 5 minutes at 95°C followed by a 5°C/minute 
temperature decrease to 25°C. Annealed dsDNA templates were then in vitro transcribed using the 
HiScribe T7 Quick High Yield RNA Synthesis Kit (New England Biolabs, Ipswich, MA) using overnight 
incubation as described in the protocol for <0.3kb transcripts [250]. CrRNAs were purified using 
RNAClean XP magnetic bead purification (Beckman Coulter, Indianapolis, IN) and quantified by 
NanoDrop spectrophotometry (ThermoFisher, Waltham, MA). 
2.2.4 LwCas13a synthesis and purification 
LwCas13a protein was synthesized and purified at the University of North Carolina at Chapel Hill 
Protein Expression and Purification Core as previously described with several modifications [240]. Briefly, 
the pET His6-TwinStrep-SUMO-LwCas13a (NovoPro, Shanghai, China) expression vector was 
transformed into Rosetta™ 2 (DE3) pLysS Singles Competent Cells (Millipore) in autoinduction media 
and grown at 37°C until OD=0.6, when the temperature was lowered to 18°C and grown overnight. The 
pellet was harvested and stored at -80°C until purification. For purification, the pellet was resuspended in 
lysis buffer (50 mM NaPO4, 500 mM NaCl, 20 mM Imidazole, 1 mM PMSF, 50 µg/mL lysozyme) and 
mixed at 4°C for 30 min. The solution was then sonicated on ice and centrifuged for 1 hour at 10,000 x g 
at 4°C. Clarified supernatant was filtered using a 0.45 micron filter. Filtered supernatant was then loaded 
over Nickel Sepharose 6 Fast Flow resin (GE). The column was washed with 5 CV Buffer A (50 mM 
NaPO4, 500 mM NaCl, 20 mM imidazole) and eluted with 10 CV Buffer B (50 mM NaPO4, 500 mM NaCl, 
500 mM imidazole). Buffer exchange was performed via dialysis to a final solution of 600 mM NaCl, 50 
mM Tris-HCl pH 7.5, 5% glycerol, and 2mM DTT. 
2.2.5 Recombinase polymerase amplification 
RPA reactions were conducted as described in TwistAmp Basic Instruction Manual (TwistDx, 
Cambridge, UK) with several modifications [251]. Each 50 µL TwistAmp reaction was subdivided by first 
creating a 45 µL mastermix and aliquoting five 5 x 9 µL reactions before adding 1 µL of sample input. 
Magnesium acetate was added to the mastermix before adding the sample input. To simulate human 
background in clinical samples, 40 ng human genomic DNA (gDNA) from buffy coat (Sigma Aldrich, St. 
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Louis, MO) was added in all experiments except those using clinical isolates. RPA reactions were 
incubated at 37°C for 30 minutes in a thermal cycler with a 40°C heated lid. After the first 4 minutes of 
incubation, samples were removed, vortexed briefly, and then returned to the thermal cycler for the 
remainder of the incubation period. 
2.2.6 Detection using LwCas13a 
LwCas13a detection reactions were performed as previously described with several 
modifications. We chose LwCas13a rather than Leptotrichia shahii Cas13a because LwCas13a has been 
demonstrated to have higher RNA-guided RNase activity than LsCas13a and is better characterized in 
the context of SHERLOCK assays [240]. Each reaction was performed using 25 μL total volume and 
contained 45 nM LwCas13, 100-500 ng crRNA, 125 nM fluorescent RNA reporter (RNAse Alert v2, 
ThermoFisher), 0.625 μL murine RNase inhibitor (New England Biolabs), 31.25 ng background RNA 
(isolated from Burkitt's Lymphoma (Raji), ThermoFisher), 1 mM rNTP mix (New England Biolabs), 0.75 μL 
T7 polymerase (New England Biolabs), 3mM MgCl2, and 1.25 uL of RPA product in nuclease assay buffer 
(20 mM HEPES, 60 mM NaCl, 6 mM MgCl2, pH 6.8) [242]. Detection reactions were conducted in 96-well 
black half-area microplates (PerkinElmer, Waltham, MA) and sealed with MicroAmp optical adhesive film 
(ThermoFisher). Detection reactions were incubated for 3 hours at 37°C on a VICTOR Nivo fluorescent 
plate reader (PerkinElmer) with fluorescence measurements taken every 5 minutes. Background 
subtracted fluorescence for each sample was calculated by subtracting the average fluorescence 
intensity of the human gDNA controls at 180 minutes of the human gDNA control from each sample. 
2.2.7 Analytical sensitivity and specificity estimation 
To determine the analytical sensitivity of the SHERLOCK assays, we performed each assay in 
triplicate using serially diluted template DNA from P. falciparum strain Dd2 (MRA-150G) for P. falciparum, 
P. vivax 18S rRNA plasmid DNA (MRA-178), P. ovale 18S rRNA plasmid DNA (MRA-180), P. malariae 
18S rRNA plasmid DNA (MRA-179), and P. knowlesi genomic DNA (MRA-456G) (Bei Resources, 
Manassas, VA). To facilitate ease of interpretation, we assumed 6 copies of 18S rRNA targets per 
genome when calculating parasite genome-equivalents [202]. Parasite DNA ranging from 105 and 10-2 
parasite genomes/µL was used to simulate expected parasite densities observed during human infection, 
including clinical malaria (typically 102 to 105 parasites/µL) and subclinical infection. Differences in mean 
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background-subtracted fluorescence were assessed using the student’s unpaired t test. We then 
performed additional biological replicates using 2-fold serial dilutions near the observed limit of detection 
to improve the precision of our analytical sensitivity estimates. Positive SHERLOCK calls were made if 
background-subtracted fluorescence was positive. Finally, we assessed each assay’s analytical 
specificity using high-concentration DNA for all human-infecting Plasmodium species, including gDNA 
and 18S rRNA plasmid DNA as described above and containing 100,000 parasite genome-equivalents 
per microliter. 
2.2.8 Clinical sensitivity and specificity estimation 
We assessed the clinical sensitivity and specificity of our assays using a panel of dried blood spot 
(DBS) samples collected in the Democratic Republic of the Congo, Uganda, and Thailand. Samples were 
chosen out of convenience; a summary of the sources of clinical samples is provided in Table 2.3. DRC 
samples were collected from subjects presenting to government health facilities with symptoms of malaria 
in Kinshasa, South Kivu, and Bas-Uele Provinces in 2017 as part of a separate study of malaria rapid 
diagnostic test performance [252]. Ugandan samples were collected from febrile children presenting to 
public health facilities located in the Kasese District of western Uganda over the period November 2017 to 
June 2018 [253]. Thai samples were collected from patients presenting to public health clinics and found 
to be smear-positive for P. vivax and as part of ongoing entomological surveillance in the Mae Sod district 
of Tak Province, northwest Thailand in 2010. All enrolled subjects provided informed consent. Ethical 
approvals were obtained by the Kinshasa School of Public Health, Mbarara University of Science and 
Technology, Uganda National Council for Science and Technology, Walter Reed Army Institute of 
Research, Ministry of Public Health in Thailand, and the University of North Carolina at Chapel Hill. 
The presence and species of Plasmodium in each sample was determined using real-time PCR. 
Prior to DNA extraction, DBS were stored at -20 or -80°C in sealed plastic bags with desiccant. Briefly, 
DNA was extracted from three 6 mm DBS punches using Chelex-100 and saponin for DRC samples, 
Chelex-100 and Tween for Uganda samples, and the QIAamp DNA mini kit (QIAGEN, Hilden, Germany) 
for Thailand samples prior to storage at -20°C [254,255]. DRC samples were first subjected to a pan-
Plasmodium real-time PCR assay targeting the 18S rRNA gene [256]. Positive samples were then 
subjected to four species-specific, semi-quantitative 18S rRNA real-time PCR assays for P. falciparum, P. 
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ovale, P. malariae, and P. vivax [204,257,258]. Parasite densities for all DRC and Uganda samples were 
determined using quantitative real-time PCR targeting the single-copy P. falciparum lactate 
dehydrogenase gene as previously described [259,260]. P. vivax infection was diagnosed and parasite 
densities determined in Thailand using microscopy at the time of DBS collection and later confirmed using 
qualitative, species-specific 18S rRNA real-time PCR for P. vivax [257,258]. PCR primers, probes, and 
reaction conditions are described in Appendix A. 
We first assessed the performance of all three assays using a panel of 11 DNA samples from 
real-time PCR-confirmed Plasmodium infections, including the four major human species (no P. knowlesi 
clinical isolates were available) and a range of parasite densities. We further characterized the 
performance of the P. falciparum assay using a panel of 62 PCR-positive and 50 PCR-negative samples 
collected in the DRC and Uganda. Plasmodium SHERLOCK assays were performed in triplicate for the 
panel of 11 DNA samples and once for the 112 samples collected in the DRC and Uganda. To improve 
specificity, positive SHERLOCK calls were made if the absolute fluorescence was at least 20% above 
background fluorescence. Clinical sensitivity, clinical specificity, and Cohen’s Kappa coefficient were 
calculated using real-time PCR as the gold standard. 
2.2.9 Parasite DNA detection in mosquito pools using SHERLOCK 
Parasite DNA was extracted from insectary-reared Anopheles dirus mosquitoes fed on blood from 
gametocytemic P. falciparum-infected volunteers in Cambodia. Mosquitoes were saved 9 and 16 days 
post-feeding to capture oocyst-stage and sporozoite-stage infection, respectively. They were pooled in 
groups of 10 and preserved in 95% ethanol before undergoing DNA extraction via a simplified Chelex 
protocol as previously described [261]. SHERLOCK assays were performed on DNA from mosquito pools 
in triplicate. Comparison of mean background-subtracted fluorescence values was performed using the t-
test as described above. 
2.2.10 Deep sequencing of clinical samples and dhps genotyping 
We selected 463 DNA samples from the DRC with P. falciparum mono-infection by real-time PCR 
for dhps genotyping using a multiplex real-time PCR assay that discriminates wild-type (A581) from 581G 
mutants (see Appendix A for details) [207]. We then selected samples for amplicon-based deep 
sequencing, including a subset of 92 wild-type and 581G mutant DNA samples identified during dhps 
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real-time PCR screening of DRC samples and 92 P. falciparum histidine-rich protein 2-based RDT-
positive samples from Uganda. Each of these 184 samples was amplified using a barcode-labeled 
forward and reverse primer (Table 2.4). PCR reactions were carried out in a total volume of 50 µL and 
using 5 µL of input DNA. The reaction mixture contained 1X Accuprime PCR buffer II (Invitrogen, 
Carlsbad, CA), 1 unit Accuprime HiFi taq, 1 µL of 0.0025 mg/µL BSA, and 400 nM of forward and reverse 
primer. The reaction conditions were 95°C for 2 minutes, followed by 40 cycles of 95°C for 30 seconds, 
60°C for 30 seconds and 68°C for 1 minute, with a final extension of 68°C for 10 minutes. PCR products 
were quantified using picogreen on a microplate reader. Amplicons were pooled, prepared for sequencing 
using Kappa HyperPrep Kits (Roche, Indianapolis, IN) and sequenced on a single MiSeq (Illumina, San 
Diego, CA) run using 250 bp paired-end chemistry at the University of North Carolina at Chapel Hill High 
Throughput Sequencing Facility.  
Sequencing data was analyzed using SeekDeep v2.6.5 using default parameters [262]. Briefly, 
data were demultiplexed using the dhps primers and a dual barcoding scheme, and final haplotypes for 
each sample were determined by removing low per-base quality scores and low frequency mismatches. 
Final haplotypes were further filtered by removing haplotypes with <2,000 reads within samples. We then 
selected DNA from samples containing a single variant consistent with a wild-type or 581G mutant 
parasite for SHERLOCK SNV testing. Mixed infections were excluded. Wild-type parasites were stratified 
by sampling location and selected for SHERLOCK testing using a random number generator (Excel, 
Microsoft, Seattle, WA). 
2.2.11 Dhps SNV detection by SHERLOCK 
All dhps SNV-detection SHERLOCK assays were performed in triplicate using the conditions 
described above. Positive SHERLOCK calls were made if background-subtracted fluorescence was 
positive. Clinical sensitivity, clinical specificity, and Cohen’s Kappa coefficient were calculated using deep 
sequencing calls as the gold standard. 
2.2.12 Statistical analysis 
Statistical analyses were performed in Prism (GraphPad, San Diego, CA) and R (R Core Team, 
Vienna, Austria). Comparisons were made using the t-test for continuous variables. Probit analysis was 
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used to determine the 95% limit of detection and 95% confidence intervals for each SHERLOCK assay. 
Samples were not randomized and experimenters were not blinded in conducting these experiments. 
2.3 Results 
We translated SHERLOCK to malaria by designing and screening candidate RPA primers and 
crRNAs, optimizing assay conditions, and validating them on clinical and mosquito samples collected in 
diverse sites. Assay development included the design and testing of two broad categories of RPA primers 
and crRNAs. The first design targeted conserved and variable regions of the Plasmodium 18S rRNA gene 
and enabled detection and species identification of Plasmodium parasites in clinical samples and 
mosquitoes. The second design included engineered crRNA-target mismatches to enable detection of the 
P. falciparum 581G mutation associated with resistance to sulfadoxine. A range of reaction parameters 
were tested during pilot testing. While we were unable to replicate the “one-pot” reaction approach 
(combining RPA, T7 transcription, and Cas13a detection) previously described for viral targets, we 
achieved best performance using a two-step reaction format (RPA followed by T7 transcription and 
Cas13a detection) and 10-50-fold higher crRNA concentrations than those originally described by 
Gootenberg et al. [240,242]. 
2.3.1 Plasmodium SHERLOCK achieves robust analytical sensitivity and specificity 
Our SHERLOCK assays demonstrated attomolar (10-18 M) analytical sensitivity for Plasmodium 
DNA, equivalent to 95% lower limits of detection (LODs) of 2.5-18.8 parasite genomes per reaction (4.2-
31.3 aM; Figure 2.6, Table 2.5) for all three assays. Using only 1 µL of initial DNA input, this is roughly 
equivalent to 2.5-18.8 parasites/µL. These sensitivities approach those of commonly deployed malaria 
real-time PCR assays, which achieved 0.3-2.5 parasites/µL analytical sensitivities during head-to-head 
testing in one controlled setting [263,264]. The pan-Plasmodium and P. falciparum SHERLOCK assays 
achieved superior LODs compared to P. vivax, but all three assays achieved LODs well below those 
detected by commonly used malaria RDTs (Table 2.5).  
To test the specificity of our SHERLOCK assays against different Plasmodium species, we 
conducted assays using high concentration 18S rRNA plasmid DNA or gDNA from five human-infecting 
Plasmodium species (Figure 2.7). The pan-Plasmodium SHERLOCK assay detected all five Plasmodium 
species tested, while the P. falciparum SHERLOCK assay only displayed activity against P. falciparum 
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gDNA. The P. vivax SHERLOCK assay detected P. vivax 18S rRNA plasmid DNA, but also demonstrated 
low-level cross-reactivity for P. knowlesi gDNA. 
2.3.2 SHERLOCK performs well in clinical samples and infected mosquitoes 
Our SHERLOCK assays successfully detected and differentiated the four most common 
Plasmodium spp. known to cause human malaria from clinical samples across a range of parasite 
densities. When applied to a panel of real-time PCR-positive clinical isolates from the DRC and Thailand, 
the species-specific P. falciparum and P. vivax assays demonstrated complete clinical specificity (Figure 
2.8). When applied to a larger panel of 62 PCR-positive and 50 PCR-negative samples from the DRC and 
Uganda, the P. falciparum SHERLOCK assay’s sensitivity and specificity were 94% and 94%, 
respectively, compared to real-time PCR (Figure 2.9, Table 2.6). The four PCR-positive/SHERLOCK-
negative samples had positive SHERLOCK results upon repeat testing, suggesting operator error or 
stochastic amplification failure during the initial assay. When SHERLOCK was performed in singleton, 
Cohen’s kappa was 0.87, consistent with excellent agreement between methods. 
The P. falciparum SHERLOCK assay also performed well when applied to DNA extracted from 
pooled, infected mosquitoes (n=4) (Figure 2.8). In all cases, the P. falciparum SHERLOCK assay was 
able to detect the presence of parasites, including both the sporozoite and oocyst stages within the 
sporogonic life cycle.  
2.3.3 SHERLOCK can be used to detect SNVs associated with antimalarial drug resistance 
Amplicon-based deep sequencing was performed to distinguish wild-type and 581G mutant dhps 
P. falciparum infections in 185 samples from the DRC and Uganda collected from patients with 
symptomatic malaria. The 581G mutation is associated with high-level resistance to sulfadoxine. The 
median read count per sample was 81,775. After filtering, only two variants were observed across all 
samples, corresponding to wild-type and 581G mutant dhps. Forty-three samples that were confirmed to 
be mono-infections bearing only wild-type or 581G mutant dhps mutations were selected for testing by 
SHERLOCK. 
When applied to 22 wild-type and 21 581G mutant dhps samples from Uganda, the sensitivity 
and specificity of the P. falciparum dhps SHERLOCK assay were 73% and 100%, respectively, using 
dhps deep sequencing calls as the gold standard (Figure 2.10). Cohen’s kappa was 0.72, consistent with 
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good agreement between SHERLOCK and amplicon-based deep sequencing. When restricted to field 
samples with parasite densities of ≥420 parasites/µL, the dhps SHERLOCK assay’s clinical sensitivity 
and specificity were 100% and 100%, respectively. Among these higher parasite density samples, 
Cohen’s kappa was 1.0, consistent with perfect agreement between the dhps SHERLOCK assay and 
amplicon-based deep sequencing in these samples with higher parasite densities.   
32 
Oligonucleotide Sequence (5’ to 3’) 
18S RPA forward primer GAAATTAATACGACTCACTATAGGGACGAAAGTTAAGGGAGTGAAGACG
ATCAGATACCG 
18S RPA reverse primer GCCCCAGAACCCAAAGACTTTGATTTCTCATAAGG 















































Detector type crRNA WT mismatches Mut mismatches Mismatch positions 
Wild-type 1 0 1 3,5 
2 1 2 3,5 
3 0 1 4,6 
4 1 2 4,6 
Mutant 5 1 0 3,5 
6 2 1 3,5 
7 1 0 4,6 
8 2 1 4,6 
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Parasites/µL (replicates detected / replicates tested) 
SHERLOCK 
Assay 
LOD (95% CI) 105 104 103 102 20 15 10 5 2.5 1.25 
Pan-Plasmodium 2.5 (1.9-21.3) 3/3 3/3 3/3 3/3 - - 20/20 20/20 19/20 14/20 
P. falciparum 6.8 (5.3-11.6) 3/3 3/3 3/3 3/3 - - 20/20 17/20 9/20 8/20 
P. vivax 18.8 (13.3-146.3) 3/3 3/3 3/3 3/3 20/20 20/20 10/20 19/20 - - 
 
 
Table 2.5. 95% lower limits of detection (LOD) for Plasmodium spp. SHERLOCK assays. Input is 1 µL of 





 Parasites/µL SHERLOCK 
Call 
 Parasites/µL SHERLOCK 
Call 
55,287 Positive  4,727 Positive  720 Positive 
52,378 Positive  4,402 Positive  679 Positive 
39,435 Positive  4,351 Positive  670 Positive 
28,996 Positive  4,194 Positive  521 Negative 
18,367 Positive  3,786 Positive  420 Positive 
17,048 Positive  3,496 Positive  365 Positive 
17,016 Positive  3,244 Positive  319 Positive 
16,463 Positive  2,723 Positive  281 Positive 
15,320 Positive  2,712 Positive  199 Positive 
15,245 Positive  2,695 Positive  192 Positive 
11,746 Positive  2,182 Positive  146 Positive 
11,746 Positive  1,965 Negative  135 Positive 
9,330 Positive  1,912 Positive  119 Negative 
9,052 Positive  1,690 Positive  111 Positive 
8,796 Positive  1,673 Positive  63 Positive 
7,906 Positive  1,046 Positive  54 Positive 
7,531 Positive  1,022 Positive  21 Negative 
6,994 Positive  956 Positive  17 Positive 
6,751 Positive  938 Positive  16 Positive 
5,841 Positive  867 Positive  3 Positive 
5,588 Positive  790 Positive    
 
 
Table 2.6. Parasite densities determined by quantitative real-time PCR targeting pfldh compared to P. 
falciparum SHERLOCK results (performed in singleton). The four negative samples were positive by 




Figure 2.1. SHERLOCK reaction workflow. (A) DNA extracted from a patient with malaria or infected 
mosquito is subjected to (B) RPA including T7 promoter-tagged primers for amplification of the 
Plasmodium 18S rRNA or P. falciparum dhps genes, followed by (C) in vitro transcription (IVT) and 
LwCas13a:crRNA complex binding to genus-, species-, or genotype-specific target RNA. This binding 
triggers collateral (D) activation of LwCas13a RNAse activity and cleavage of reporter RNA, separating 
the fluorescent reporter from its quencher and producing a signal. Abbreviations: RPA, recombinase 




Figure 2.2. SHERLOCK is capable of distinguishing the dhps 581G SNV associated with antimalarial 





Figure 2.3. P. falciparum crRNA screen. Pf 2 was selected for further testing based on its background-
subtracted fluorescence. Input: P. falciparum 18S rRNA plasmid equivalent to 100,000 parasites/µL. N = 




































Figure 2.4. P. vivax crRNA screen. Pv 2 was selected for further testing based on its background-
subtracted fluorescence. Input: P. vivax 18S rRNA plasmid equivalent to 100,000 parasites/µL. N = 3 



































Figure 2.5. Dhps crRNA screen. Dhps crRNA 5 was selected for further testing in the 581G SNV-
detecting SHERLOCK assay based on its high mutant:wild-type background-subtracted fluorescence 
ratio. Wild-type (WT) gDNA: Dd2 strain P. falciparum equivalent to 100,000 parasites/µL. Mutant (Mut) 
gDNA: K1 strain P. falciparum equivalent to 100,000 parasites/µL. N = 3 technical replicates, n = 1 






































Figure 2.6. Analytical sensitivity of Plasmodium spp. SHERLOCK assays. (a) Pan-Plasmodium assay vs. 
P. falciparum strain 3D7 gDNA (b) Pan-Plasmodium assay vs. P. vivax 18S rRNA plasmid DNA (c) P. 
falciparum assay vs. P. falciparum strain 3D7 gDNA (d) P. vivax assay vs. P. vivax 18S rRNA plasmid 
DNA. N = 3 technical replicates, n = 1 biological replicate. Unpaired student’s t test vs. NTC, ± SEM. 




Figure 2.7. Analytical specificity of Plasmodium spp. SHERLOCK assays (a) Pan-Plasmodium 
SHERLOCK assay can detect five Plasmodium species in humans, while (b) P. falciparum, and (c) P. 
vivax SHERLOCK assays can differentiate between Plasmodium species. Input for all species was the 
equivalent of 100,000 parasites/µL as either species-specific 18S plasmid or gDNA n (P. knowlesi only). 
N = 3 technical replicates, n = 1 biological replicate. Unpaired student’s t test vs. NTC, ± SEM. 




Figure 2.8. (a) Pan-Plasmodium, (b) P. falciparum, and (c) P. vivax SHERLOCK assays successfully 
detected and differentiated Plasmodium infections in diverse clinical isolates. (d) P. falciparum 
SHERLOCK assay detected both the oocyst and sporozoite stages of DNA extracted from infected 
mosquitos. Pf gDNA in the mosquito assay was 100,000 parasites/µL. Parasite densities were 
determined by qPCR for Pf, Pm, and Po and by microscopy for Pv. N = 3 technical replicates, n = 1 
biological replicate. Unpaired student’s t test vs. NTC, ± SEM. Abbreviations: Pf, P. falciparum; Pv, P. 
vivax; Pm, P. malariae; Po, P. ovale; NTC, no template control; gDNA, genomic DNA; Sub, subject.  
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Figure 2.9. Receiver-operator curve for P. falciparum SHERLOCK assay tested on 62 real-time PCR-
positive and 50 real-time PCR-negative clinical isolates. Points represent candidate thresholds for a 
positive SHERLOCK call, using the formula (absolute fluorescence of sample)/(absolute fluorescence of 
negative control)x100 to calculate threshold percentages. A signal of 20% above background was 
selected as the cutoff for a positive call, yielding 94% sensitivity and 94% specificity compared to real-














































Figure 2.10. The dhps SHERLOCK assay detects P. falciparum parasites with (a) mutant (581G) but not 
(b) wild-type (A581) alleles. Parasite densities were determined by qPCR. N = 3 technical replicates, n = 





We describe a suite of novel SHERLOCK malaria assays and highlight the versatility of CRISPR-
based diagnostics for a range of infectious disease applications. The new assays achieved robust clinical 
sensitivity and specificity when applied to well-characterized clinical samples and were easily adapted for 
parasite detection in mosquitoes and for drug-resistance genotyping. New diagnostics that can be used to 
detect, identify species, and genotype P. falciparum infections rapidly and reliably are especially needed 
in sub-Saharan Africa, where 94% of malaria deaths occur [265]. 
These SHERLOCK malaria assays outperform HRP2-based RDTs, the predominant malaria 
diagnostic modality deployed throughout Africa, and achieve similar performance to recently developed 
ultrasensitive HRP2-based RDTs, which have achieved clinical sensitivities of roughly 3 parasites/µL 
[188,266]. Increasing reports of P. falciparum with deletion mutations of the histidine rich 2 and/or 3 
genes raise concerns about reliance on HRP2 as the primary diagnostic target for RDTs [267]. RDTs that 
detect alternative antigens such as pLDH are available, but they are less sensitive and less heat-stable 
than HRP2-based RDTs. Thus, there is a need for novel malaria diagnostics that detect other targets. 
While both SHERLOCK and other CRISPR-based diagnostic assays currently in development need 
additional optimization prior to field deployment, we demonstrate that they are easily adapted for specific 
use cases and represent a promising avenue for malaria diagnostic development. 
The analytical and clinical sensitivity of these SHERLOCK malaria assays approached that of 
commonly used real-time PCR assays, but the ability to conduct SHERLOCK without thermocycling 
allows for reduced laboratory infrastructure requirements and enables simplified isothermal approaches. 
More recently developed “ultrasensitive PCR” assays that target RNA and/or multicopy genes have 
achieved analytical sensitivities as low as 0.02 parasites/µL, but their use in low-resource laboratory 
settings is limited by the need to protect against RNA degradation and/or the requirement for large-
volume samples [203,268]. LAMP is an alternative nucleic acid detection method that has been used for 
malaria diagnosis in field settings with similar sensitivity and specificity to SHERLOCK [269]. LAMP 
shows promise as a field-deployable molecular diagnostic, but its use for bespoke applications has been 
hampered by the complexity of target selection and primer design. CRISPR-based diagnostic approaches 
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like SHERLOCK are an emerging technology that can be rapidly adapted in response to malaria’s 
evolving epidemiology [270]. 
Species discrimination was excellent across Plasmodium spp. SHERLOCK assays, with the 
exception of the P. vivax SHERLOCK assay that demonstrated cross-reactivity with P. knowlesi. The P. 
vivax spacer and the analogous region on P. knowlesi differ by four nucleotides, so this cross-reactivity 
was unexpected. One explanation is that these nucleotides are towards the 3’ end of the crRNA spacer 
(positions 20, 26, 27 in the 28), which have been shown to have a smaller influence on crRNA binding 
efficiency [240]. Another explanation is unappreciated homology between P. vivax and P. knowlesi spacer 
binding sites in the setting of incomplete understanding of P. knowlesi’s genetic diversity. These findings 
highlight the importance of using high-quality genomic data when designing target sequences for 
CRISPR-based diagnostics and consideration of sequence variability within targets. Future SHERLOCK 
assays will be strengthened by efforts to improve our understanding of parasite genomic diversity 
[271,272]. 
Our novel SNV-detection SHERLOCK assay for the dhps 581G variant in P. falciparum 
represents one of the first uses of SHERLOCK to detect SNVs in clinical isolates outside of its original 
description [240,242]. We chose to develop a SHERLOCK SNV-detection assay for Plasmodium dhps 
variants due to their public health importance in the prevention of malaria during pregnancy. Variants in 
the dhps gene can confer resistance to sulfadoxine, which is used in combination with pyrimethamine as 
the primary antimalarial drug for intermittent preventive treatment in pregnancy to prevent malaria in 
pregnancy throughout much of sub-Saharan Africa [273]. Our dhps SHERLOCK assays demonstrated 
parasite-density dependent sensitivity and perfect specificity when compared to amplicon-based deep 
sequencing. When applied to a wide range of parasite inputs, the assay only produced false-negative 
results in samples with low parasite densities (6/7 samples with ≤319 parasites/µL sample input). While 
the SNV-detection assay is concentration dependent, it performed well at parasite densities typically 
associated with clinically significant malaria [274]. In future, mixed infections involving both wild-type and 
581G mutant strains could be identified by pairing the 581G-specific assay described here with a wild-
type-specific assay in a multiplexed format. SHERLOCK’s SNV detection capabilities are a promising tool 
for malaria control programs in low-resource settings where sequencing facilities are not available to 
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support surveillance. For example, high prevalence of resistance-associated dhps variants detected by 
SHERLOCK could trigger deployment of alternative drug regimens for IPTp in affected regions. 
Our SHERLOCK assays are now one of two published CRISPR-based diagnostic modalities for 
Plasmodium detection; in a recently published manuscript, Lee et. al. describe a suite of highly sensitive 
and specific assays for P. falciparum, P. vivax, P. malariae, and P. ovale spp [275]. Though described as 
SHERLOCK, these assays employ a detection approach most similar to the DNA endonuclease-targeted 
CRISPR trans reporter (DETECTR) methodology, which uses the DNA endonuclease Cas12 [239]. While 
our methods differ in this regard, both approaches highlight the potential uses for SHERLOCK and other 
CRISPR-based diagnostics for malaria diagnosis, research, and drug resistance surveillance. 
The assays described by Lee et al. have several advantages and disadvantages compared to our 
assays. First, the analytical sensitivity achieved by Lee et al. is superior. The 95% lower LODs of their P. 
falciparum and P. vivax assays were 0.36 (0.23-1.0) and 1.2 (0.52-6.2) parasites/µL compared to our 
95% lower LODs of 6.8 (5.3-11.6) and 18.8 (13.3-146.3), respectively. One explanation for this improved 
performance is that Lee et al. chose gene targets that are present in higher copy numbers: Pfr364 
subtelomeric repeat DNA for P. falciparum (41 copies) and mitochondrial DNA for P. vivax (up to 20 
copies) vs. 18s rRNA in our assays (~6 copies). While the use of 18S rRNA targets reduces assay 
sensitivity, it provides opportunities for streamlined, multiplexed assays that employ a single, shared RPA 
primer set targeting regions that are conserved across Plasmodium species and bespoke crRNAs for 
species identification. Second, Lee et al. describe streamlined approaches to nucleic acid extraction and 
reaction set-up that are better suited for field use. These advances make it clear that some of the 
challenges we encountered with our Cas13a-based SHERLOCK approach can be overcome. Third, the 
clinical performance of the assays described by Lee et al. is not yet defined. They conducted validation 
experiments using a panel of simulated samples derived from cultured parasites and a small number of 
serum samples, whereas we validated our assays on dried blood spot samples collected in malaria 
endemic countries, including a large panel of 112 samples for our P. falciparum assay. This type of 
clinical validation is important because samples collected under field conditions is necessary to define 
real-world assay performance, both in terms of sample preparation/integrity and parasite genetic diversity. 
Genetic diversity of sites targeted by these assays can only be partly deduced from publicly available 
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sequencing data, especially in the case of non-falciparum species like P. ovale and P. malariae that are 
not well represented in existing databases. Despite these differences, the performance of both sets of 
CRISPR-based diagnostic assays demonstrates that they can detect parasite concentrations well below 
what is expected in clinical malaria and supports future studies to adapt and validate these assays for use 
in research and clinical settings. 
We chose LwCas13a-based detection over a Cas12a-based approach to take advantage of 
Cas13a’s minimal protospacer-adjacent motif (PAM) site nucleotide requirements compared to Cas12a. 
LwCas13a requires only H (not G) adjacent to the spacer region, which makes guide design and SNV 
detection for LwCas13a easier than for Cas12a, which has a PAM requirement of “TTTN” [238,239]. 
Additionally, multiplexing with SHERLOCK has been demonstrated using Cas13a isolated from multiple 
bacterial species, which have different collateral activities that can be used to activate different RNA 
reporters, enabling multiplexed assays [242]. These properties of Cas13a provide opportunities for further 
assay development, including translation of our malaria SHERLOCK assays into a single, multiplexed 
assay that enables species identification of multiple Plasmodium species and drug-resistance SNVs in a 
single reaction. We experienced success using SHERLOCK to detect Plasmodium spp. and drug-
resistance variants; however, several limitations must be overcome for successful translation of 
SHERLOCK from the laboratory to the field. First, we could not achieve the sub-attomolar limits of 
detection or “one-pot” reaction conditions previously described for viral targets [242]. We also observed 
that our assays performed best using higher crRNA concentrations than those originally described [240]. 
Though this may reflect differences in crRNA synthesis or lot-to-lot variation in other reagents, we 
observed improved reaction performance with higher crRNA concentrations across multiple experiments. 
Second, the cost of designing and validating a SHERLOCK assay is not trivial. In a reaction 
volume of 25 µL used for 96-well plates and using fluorescent output, the cost was roughly equivalent to 
PCR at over $2.00 of reagent costs per technical replicate, plus upfront costs of crRNA optimization and 
synthesis and the need for a fluorescence plate-reader. These costs can be reduced for assays brought 
to scale but are an important consideration during assay design. Finally, SHERLOCK requires multiple 
reagents, custom crRNAs, and Cas13a. Recent progress has been made to reduce its complexity and 
make these assays more easily accessible [276]. Indeed, the approach described by Lee et. al includes a 
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streamlined workflow from sample collection to Cas12a-based detection; including an optimized nucleic 
acid extraction step, one-pot lyophilized reaction, reduced reaction time, and a handheld fluorometer and 
lateral-flow readout. Other groups have sought to replace RPA preamplification with LAMP, or eliminate it 
altogether in the case of one Cas13a-based SARS-CoV-2 diagnostic [277,278]. While these advances 
confirm rapid improvements in CRISPR-based assay performance and feasibility, implementation of 
SHERLOCK as a point-of-care molecular diagnostic will require further streamlining including the 
development of commercially-available master mixes and the combination of nucleic acid extraction, Cas 
effector activation, and signal readout into a single device. 
While these limitations must be overcome before immediate field applications, SHERLOCK is a 
promising technology with multiple potential uses in malaria diagnosis, research, and drug resistance 
surveillance. In particular, our SNV-detection SHERLOCK assays demonstrate applications beyond 
infectious disease diagnosis and include genotyping pathogens at the nucleotide level. With further 
optimization, our SNV-detection assays could facilitate drug resistance surveillance for malaria control 
programs without the need for PCR or sequencing. Additionally, our pilot application of SHERLOCK to 
detect P. falciparum in infected mosquitoes demonstrates potential beyond clinical diagnostics and other 
uses for research in low malaria transmission or near elimination settings. Continued development of new 
Cas effectors, streamlined workflows, and point-of-care read-outs will open new opportunities for CRISPR 
diagnostics in clinical, surveillance, and research applications. These novel malaria SHERLOCK assays 
confirm the promise of CRISPR-based diagnostics for diverse applications and in resource-limited 
settings. 
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CHAPTER 3: POPULATION GENETICS OF THE P. FALCIPARUM DHPS 581G VARIANT IN THE 
DEMOCRATIC REPUBLIC OF THE CONGO 
3.1 Introduction 
3.1.1 Sequencing for malaria genomics 
Since the mid-20th century, researchers in the fields of genetics, biochemistry, and molecular 
biology have made significant progress in characterizing the physiology, metabolic pathways, and life 
cycle of the Plasmodium parasite [279]. Beginning in the late 20th century and continuing into the 21st, 
advances in high-throughput nucleic acid sequencing and bioinformatic analysis have made it possible to 
interrogate these questions beyond a single gene or protein but at the level of the genome [233]. By 
taking this broader view, malaria genomics has facilitated the study of relationships between parasite 
populations and their changes over time, including the evolution of antimalarial resistance. To accomplish 
this, several methodological challenges must first be overcome including the selective amplification and 
sequencing of Plasmodium DNA and the deconvolution of the resulting genomic data. 
Although Plasmodium parasites primarily infect enucleated erythrocytes, there is typically enough 
human genomic DNA present in clinical isolates to overwhelm Plasmodium DNA in most sequencing 
approaches. While PCR is an effective preamplification method for amplicon sequencing, alternative 
techniques are needed for genome-wide approaches [280]. One approach to overcoming this obstacle is 
selective whole genome amplification (SWGA), which consists of a preamplification step using primer sets 
designed to preferentially amplify target DNA using a highly processive polymerase [281]. When applied 
to P. falciparum, sWGA results in over 18-fold enrichment of parasite DNA compared with nonselective 
whole genome amplification [282]. Importantly, the level of enrichment afforded by sWGA makes it 
practical to conduct malaria genomics using DNA collected from DBS rather than bulk venous blood, 
overcoming a significant obstacle to conducting such studies at scale in low- and middle-income 
countries. The method has limitations due to “jackpotting” during amplification, where certain regions of 
the genome are disproportionately amplified relative to other regions. However, this appears to be 
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random and is alleviated by conducting multiple SWGA reactions simultaneously and sequencing the 
pooled amplifications. An alternate approach is the use of hybrid selection, where biotinylated DNA or 
RNA baits are designed complementary to the parasite genome and used to “capture” complementary 
parasite DNA in the sample. This technique is robust and has been used successfully in malaria, 
however, the high reagent costs each array makes it less suitable for large numbers of samples. 
The choice of sequencing modality for malaria genomics is a trade-off between the quantity 
(number of independent sites to be sequenced) and quality (read depth) with cost, throughput, and the 
particular research question being asked. Amplicon-based sequencing limits the search to predefined loci 
of interest, such as genes associated with antimalarial resistance or vaccine antigens [283,284]. To query 
multiple loci simultaneously, amplicon-based approaches can be broadened and multiplexed using panels 
of PCR primers, molecular inversion probes, and the CRISPR/Cas9-based enrichment method Finding 
Low Abundance Sequences by Hybridization [285–287]. Multiplexed amplicon-based sequencing 
approaches can also be used to distinguish parasite strains and geographic subpopulations by using well-
characterized microsatellite regions and SNVs that vary geographically to generate “molecular barcodes” 
[288–290]. However, while amplicon-based methods can provide useful insight into the distribution of 
drug resistance alleles and population genetics, whole genome sequencing approaches can analyze 
hundreds of thousands of variants and are becoming more practical as sequencing costs continue to 
decline [291].  
A challenge to malaria genomic analysis is the presence of clinical infections by multiple 
genetically distinct parasite lineages that may differ with respect to geographic origin, drug resistance 
profile, or other characteristics of interest. To accurately analyze genomic data from these polyclonal 
infections, the number of parasite strains present, known as complexity of infection (COI), must first be 
deconvoluted. One method to addressing this challenge is Turning HEterozygous SNP data into Robust 
Estimates of ALelle frequency, via Markov chain Monte Carlo, better known by the award-winning forced 
acronym THE REAL McCOIL [292]. THE REAL McCOIL is a Bayesian approach that estimates allele 
frequency and COI using SNV data from polyclonal parasite samples. This differs from a previous 
approach, Complexity Of Infection using Likelihood (COIL), which relies on allele frequencies from 
monoclonal samples or external datasets to determine COI [293]. This is problematic because allele 
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frequencies in P. falciparum can have significant geographic and temporal variation. By not relying on 
these assumptions, THE REAL McCOIL is superior at estimating allele frequency, COI, and relatedness 
in polyclonal parasite samples. 
3.1.2 Translational applications of sequencing for malaria genomics 
One translational application of malaria genomics is to determine how much malaria transmission 
is occurring in a given area. Transmission intensity can be measured in terms of numbers of cases per 
capita, seropositivity, and entomological inoculation rate - the number of infectious bites per person per 
year - but these measures are often incomplete and imprecise estimates [291]. Alternatively, genomic 
approaches can be used to measure transmission intensity using population-level COI estimates and 
linkage disequilibrium (LD) - the nonrandom association of alleles of different loci - within parasite 
populations [294–296]. Higher entomological inoculation rate is associated with higher COI, as multiple 
infectious mosquito bites introduce different parasite clones into a human host. Conversely, as 
transmission intensity decreases, parasite strains encounter genetic bottlenecks and infections become 
more clonal. LD also varies with COI; infection by multiple parasite clones facilitates higher recombination 
rates within the mosquito, leading to shorter haplotype blocks and decreased LD. In the context of 
monitoring transmission intensity, population-level COI estimates are the most responsive to short-term 
changes (such as a successful malaria control program), whereas LD is most reflective of the long-term 
history of a parasite population’s transmission intensity. By analyzing these variables, the relationship 
between transmission intensity, COI, and LD can be used to detect importation of malaria from a high 
transmission setting (high COI, low LD) to near-elimination settings (low COI, high LD) [297].  
Analyzing genome-wide variation in a large number of samples is a daunting challenge, as the 
number of interactions increases exponentially with each additional variable and sample. One approach 
to addressing this is through principal component analysis (PCA), which reduces the dimensionality of 
this matrix into principal components while preserving as much variation as possible [298]. Applying PCA 
to malaria genomics as an exploratory data analysis method can categorize parasite subpopulations 
based on regional genomic variation and determine which loci are responsible for regional genomic 
divergence [299].  
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Another practical application of translational malaria genomics is to search for evolutionary 
selection at a particular locus, especially for genes associated with antimalarial resistance. One method 
for doing so is to analyze patterns of identity by descent (IBD), or the proportion of alleles that have been 
directly inherited from a common ancestor [300]. IBD is not absolute; rather, it is compared in a pairwise 
manner between two samples within a given set and in reference to an ancestral haplotype. IBD ranges 
between zero in unrelated individuals to one in identical clones. Meiotic recombination disrupts haplotype 
blocks, weakens linkages between alleles and decreases IBD. This is in contrast to identity by state 
methods of analyzing genetic relatedness, which share an allele at a given site but may be due to chance 
or convergent evolution in addition to recent evolutionary history [301].  
The search for genomic regions under selection can also be analyzed in terms of number of 
segregating sites by length (nSL) [302]. nSL differs from other methods of analysis by measuring the 
length of a haplotype under potential selection in terms of the number of co-segregating variants. This 
method is sensitive for detecting both hard and soft selective sweeps, and has the advantage of not 
requiring a genomic recombination map for analysis.  
Extended haplotype homozygosity (EHH) is another metric that can be used to look for signatures 
of selection at a given locus [303]. Selection is often described in terms of selective sweeps, or the 
increasing frequency of a variant within the population over time. A soft selective sweep is characterized 
by a higher degree of genomic variation in the region surrounding a locus of interest and low EHH. Soft 
selective sweeps arise when there is pre-existing variation at a given locus that is then subjected to 
selective pressure. When variants that are preferentially selected become more numerous in the 
population, they co-segregate with multiple different nearby chromosomal regions, observed as 
haplotypes of variants inherited together, preserving genetic variation in the surrounding region. In 
contrast, hard selective sweeps are characterized by the presence of a low degree of genomic variation in 
the region surrounding a locus of interest and high EHH. Hard selective sweeps arise when a novel 
variant arises that confers a selective advantage, such as antimalarial resistance. Because of this 
selective advantage, the novel variant spreads rapidly through the population, carrying the nearby 
chromosomal region with it as a “hitchhiker”. Because recombination and genetic drift tend to break down 
haplotype blocks over time and generations, high EHH is evidence that a locus may be under a high level 
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of selective pressure or has emerged relatively recently in evolutionary history. EHH has been especially 
useful in detecting hard selective sweeps that have arisen from the emergence of antimalarial resistance, 
including antifolate resistance on numerous occasions [304,305]. Taken together, EHH and the other 
aforementioned modalities for analyzing evolutionary selection at a particular locus have been 
indispensable in understanding the evolution and spread of drug resistance in P. falciparum, as well as 
how this contributes to parasite population structure. 
3.1.3 Genomics of antifolate resistance in the Democratic Republic of the Congo 
Despite having only 1.3% of the world’s population, the DRC is home to 12% of the world’s 
malaria cases and 11% of deaths annually [14,15]. The majority of the population (97%) lives in a high 
transmission area, including nearly all pregnant women [124,125]. Because of the risk of malaria in 
pregnancy, IPTp with SP is a mainstay in the DRC, although only approximately 50% of pregnant women 
receive at least three doses of SP annually [7]. While efforts to expand access to IPTp are an essential 
part of malaria in pregnancy prevention, the spread of SP resistance threatens to abrogate these gains 
and compound the problem of malaria in pregnancy in the DRC.  
Concern about the spread of SP resistance is supported by previous studies using clinical 
isolates from the 2007 and 2013 Demographic and Health Surveys; PCR-confirmed infections (220 in 
2007, 552 in 2013) from across the country, the quintuple mutant haplotype (dhfr 51I, 59R, 108N, dhps 
437G, 540E) increased significantly from 17% in 2007 to 41% in 2013 [286,306]. Worse still, the sextuple 
mutant haplotype (+dhps 581G) also increased significantly from 3% in 2007 to 18% in 2013. 
Interestingly, SP resistance is not evenly distributed throughout the DRC; the eastern region of the 
country and especially the northeast region along the border with South Sudan, Uganda, and Rwanda 
has the highest frequency of quintuple mutant parasites, and the frequency of quintuple mutants 
decreases along an east to west cline. The distribution of sextuple mutants is similarly concentrated in the 
eastern region of the country, especially along the Ugandan and Rwandan border [286]. 
Because of the DRC’s location in the center of Africa, the population genetics of malaria in the 
DRC are influenced by both east African and west African parasite populations. A recent study of 2,537 
clinical isolates collected between 2013-2015 found that in addition to variants associated with different 
geographic sub-populations (northern vs. southern and eastern vs. western Africa), variants at the P. 
58 
falciparum chloroquine resistance transporter (pfcrt) and dhps loci contribute to population structure of 
parasites [299]. Interestingly, selection of the chloroquine-resistant pfcrt 76T variant differed 
geographically as well, with pfcrt 76T parasites from western DRC showing higher EHH values 
surrounding pfcrt than pfcrt 76T parasites from eastern DRC. In this previous work, we determined that 
SNVs surrounding dhps locus were impacting the differentiation of the parasite population using principal 
component analysis in PC4. Given this finding and the significant differences in prevalence of the dhps 
581G variant between east and west DRC, we sought to investigate how the dhps 581G variant 
contributes to parasite population structure in the DRC and to determine the relationship between mutant 
isolates from across the country. We hypothesized that the dhps 581G variant is undergoing positive 
selection in the DRC and that there would be common extended haplotypes surrounding the mutation 
suggesting spread of the mutation regionally in the DRC. 
3.2 Materials and Methods 
3.2.1 Sample Collection and Processing 
Whole genome sequencing was conducted on 260 P. falciparum isolates collected from subjects 
with uncomplicated or asymptomatic malaria between 2015-2018 in the DRC, Ghana, and Tanzania. 
Samples from the DRC were collected from three regions, Kinshasa (n=35), Sud-Kivu (n=44), and Bas-
Uele (n=33), as part of a study of false-negative HRP2-based RDTs (total n=112) [307]. Samples from 
Ghana were collected between 2016-2017 as part of a separate drug resistance surveillance study 
(n=13). Samples from Tanzania were collected from several studies including a 2017 school-based 
malaria parasitemia survey administered by the National Malaria Control Programme in West Tanzania 
(n=11) and several in vivo drug efficacy studies conducted between 2015-2017 (n=124) [297]. Samples 
were collected as either leukodepleted blood or DBS and extracted using QIAamp 96 DNA blood kits 
(Qiagen, Hilden, Germany). Extracted samples underwent dhps 581 genotyping using a TaqMan allelic 
discrimination assay and were selected for library preparation and sequencing based on convenience 
(e.g. samples with large volumes of extracted DNA) and were specifically enriched for samples containing 
dhps 581G variants [207]. 
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3.2.2 Library preparation and deep sequencing 
Samples from Ghana, the DRC, and the Tanzanian school-based malaria parasitemia survey 
were processed similarly. First, selective whole genome amplification (sWGA) was used to enrich DNA 
extracted from DBS for P. falciparum DNA before library preparation. To minimize the effects of 
jackpotting, three separate rounds of sWGA were conducted for each sample and pooled. Amplification 
was conducted using a pool of ten primers designed to preferentially amplify P. falciparum DNA over 
human DNA background as described in Oyola et al [282]. Pooled sWGA products were acoustically 
sheared using a Covaris E220 and prepared for Illumina sequencing using Kapa HyperPlus prep kit with 
PCR library amplification (Kappa Biosystems, Columbus, OH). Final indexed libraries were pooled and 
sequenced on a NovaSeq 6000 paired end 2×150 bp sequencer at the University of North Carolina High 
Throughput Sequencing Facility. 
Samples from Tanzanian in vivo drug efficacy studies were processed slightly differently. Instead, 
two sWGA reactions were conducted for each sample using a custom set of sWGA primers described in 
Morgan et al [297]. Pooled sWGA products were acoustically sheared using a Covaris E220 and 
prepared for Illumina sequencing using Kapa HyperPlus prep kit with PCR library amplification. Final 
indexed libraries were pooled and sequenced on a MiSeq 4000 paired end 2×150 bp sequencer at the 
University of North Carolina High Throughput Sequencing Facility. 
3.2.3 Read alignment and quality control 
Adapter sequences were trimmed from paired-end reads using ‘cutadapt’ v1.18 and aligned to 
the P. falciparum 3D7 reference genome (PlasmoDB version 38: 
https://plasmodb.org/common/downloads/release-47/Pfalciparum3D7/fasta/data/PlasmoDB-
47_Pfalciparum3D7_Genome.fasta ) with ‘bwa mem’ v0.7.17. Reads determined to be PCR duplicates 
were marked with ‘picard’ v2.21.7. Preliminary calls of short sequence variants including SNVs, indels, 
and multi-nucleotide variants were determined using Genome Analysis Toolkit (GATK) ‘Haplotypecaller’ 
tool v4.1.2.0. Coverage statistics were generated using ‘vcftools’ v0.1.16 and samples with ≦ 60% 




3.2.4 Variant calling and filtering 
Samples were combined using GATK ‘CombineGVCFs’ tool and genotyped simultaneously using 
GATK ‘GenotypeGVCFs’ according to GATK best practices. Analysis was restricted to biallelic SNVs, 
which were then filtered using GATK Variant Quality Score Recalibration, which implements a machine 
learning approach. The following genome sets were used to train the algorithm: QC-passing sites from 
the P. falciparum Genetic Crosses Project release 1.0 (ftp://ngs.sanger.ac.uk/production/malaria/pf-
crosses/1.0/, true positives) and QC passing sites from Pf3K release v5.1 
(ftp://ngs.sanger.ac.uk/production/pf3k/release_5/5.1/, true positives and false positives) [308]. A 90% 
sensitivity threshold was applied to identify and retain SNVs from the training sets. Further analysis was 
restricted to the core genome by excluding subtelomeric regions and internal var gene clusters as 
described by Otto et al [309]. The following criteria were used to further exclude variants: read depth <5, 
variants with >10% missing data, <1% minor allele frequency, and <1% population within-sample allele 
frequency. 
3.2.5 Complexity of infection (COI) analysis 
 COI was determined using Turning HEterozygous SNP data into Robust Estimates of ALelle 
frequency, via Markov chain Monte Carlo, and Complexity Of Infection using Likelihood (THE REAL 
McCOIL) with default parameters [292]. THE REAL McCOIL was repeated using 10,000 and 30,000 total 
runs with 10,000 and 2,000 burn-in runs, respectively. Estimated polyclonal samples were excluded from 
further analysis. 
3.2.6 Population genetics analysis 
Principal Component Analysis (PCA) was conducted using within-sample allele frequencies for 
the 93 samples that passed filters. Missing SNV data was imputed using average value per locus. PCA 
was conducted using the ‘prcomp’ function in R version 4.0.3. Per-locus contributions to five largest 
principal components were plotted along their chromosomal positions. PCA was also analyzed with 
respect to each sample’s geographic origin by plotting the samples by the contribution of the first and 
second principal component. Extended haplotypes of SNVs between 50 kb upstream and downstream of 




3.3.1 Variant filtering and discovery 
After excluding samples with ≦ 60% genome-wide coverage at 5x read depth and those missing 
variant calls at dhps 581, 157 out of 260 samples remained (60.4%). Within these samples, an initial 
1,593,108 short sequence variants were identified, of which 725,002 (45.5%) were biallelic SNVs and 
132,972 (18.3%) of which passed quality control. After filtering to exclude internal var genes and 
subtelomeric regions, 131,858 (99.2%) variants remained with SNV calls missing at 1.792% of total sites.  
When SNV calls with <5 reads were removed, 100% of sites remained, the proportion of missing 
SNV calls increased to 5.63%, and the median read depth for all sites increased slightly from 41.0 to 44.0 
(Figures 3.1, 3.2). After excluding sites with >10% missingness across samples, 110,918 sites remained 
(84.1%) of which 2.804% overall were missing SNV calls (Figures 3.3, 3.4). Filtering out sites with a 
minor allele frequency of <1% further reduced the number of sites by 68.5% to 34,904, of which 3.43% 
were missing SNV calls (Figures 3.5, 3.6). A final filtering step of removing sites with a population within-
sample allele frequency of <1% had little effect: 33,481 sites remained (97.0%) of which 3.426% were 
missing SNV calls (Figures 3.7, 3.8). 
3.3.2 Complexity of Infection 
COI estimates from THE REAL McCOIL were identical between 10,000 and 30,000 total runs 
with 2,000 and 10,000 burn-in runs, respectively (Figures 3.9, 3.10). For all samples, mean COI was 
1.522 with a maximum of 5. Mean COI estimates were significantly higher in samples with mixed dhps 
581 variant calls (2.11) compared with samples with wild-type (1.53, p <0.0014) and mutant dhps 581 
variants (1.21, p <0.032) (Figure 3.11). No significant difference in COI was detected between samples 
with wild-type and mutant dhps 581 variants. Mean COI estimates between locations from highest to 
lowest were Bas-Uele (1.81), West Tanzania (1.70), East Tanzania (1.53), Ghana (1.50), Sud-Kivu (1.40), 
and Kinshasa (1.30) (Figure 3.12). Mean COI was 1.49 for all samples from the DRC and 1.55 for 
Tanzania. The only statistically significant difference detected between the sites was between Bas-Uele 
and Kinshasa (p <0.035). Overall, 93 samples (59.2%) were monoclonal and were retained for principal 
component and extended haplotype analysis. 
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3.3.3 Population structure 
We conducted principal component analysis on the 93 monoclonal samples using 33,481 sites 
that passed filtering. The proportion of variance explained by the first five principal components was 
4.811%, 2.639%, 2.537%, 2.479%, and 2.417%, respectively. Cumulative variance by PC5 was 14.883%, 
after which the relative contribution of each additional principal component gradually decreased. To 
assess the influence of geography on population structure, we plotted samples by the first two principal 
components (Figure 3.13). We observed clustering of samples between East and West Africa as has 
been previously described. The distribution of samples is characterized by four outliers from Ghana (n=1) 
and East Tanzania (n=3) and a main cluster with significant overlap. Within the main cluster, there is a 
gradient of similarity along the PC2 axis from Ghana to Bas-Uele, Kinshasa, Sud-Kivu, West Tanzania, 
and East Tanzania. We then plotted only the samples from the DRC and saw a similar pattern, with 
several outlier samples and a geographic gradient along the PC2 axis from Bas-Uele to Kinshasa and 
Sud Kivu (Figure 3.14). 
To determine whether drug resistance loci were disproportionately impacting population structure, 
we plotted the relative contribution of each site across the genome for each of the first five principal 
components (Figures 3.15-3.19). Overall, the relative contribution of each locus was minimal, with a 
maximum of ~0.02% observed across the genome for the first five principal components. Importantly, we 
did not detect significant contributions to population structure from any individual loci, including dhps or 
pfcrt. 
3.3.4 Extended haplotype analysis 
Unfortunately, we had insufficient numbers of mutant samples to robustly conduct statistics for 
selective sweeps such as nSL and EHH scans.  Therefore, we used a descriptive extended haplotype 
approach that has previously been used to evaluate extended haplotypes around k13 associated with 
artemisinin resistance. Extended haplotype analysis was conducted within 50 kb upstream and 
downstream from the dhps 581 locus (Pf3D7_08_v3:550,117). Significant heterogeneity between 
samples was observed within the 100 kb surrounding the dhps 581 locus (Figure 3.20). When comparing 
A581 and 581G samples, highly-conserved extended haplotypes expected with a hard selective sweep 
were not observed (Figures 3.21, 3.22). Significant variation is also observed in the extended haplotypes 
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within geographical locations (Figures 3.23-3.28). Restricting analysis to the 581G samples, there is 
limited similarity in the 50 kb region upstream of the dhps 581 locus, with several distinct extended 
haplotypes emerging (Figure 3.21). One extended haplotype can be observed in 581G samples from the 
DRC and East Tanzania (Figure 3.21, indicated in red), and the same extended haplotype can be 
observed in A581 samples from the same region (Figure 3.25, indicated in purple). Similarly, another 
extended haplotype can be observed in 581G samples from Ghana (Figure 3.26, indicated in green) that 
is also shared with A581 samples from the same region (Figure 3.26, indicated in blue). Formalized 












Figure 3.3. Histogram of missingness for all sites pre-filtering.  
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Figure 3.6. Histogram of minor allele frequencies for all sites after removing loci with a minor allele 








Figure 3.8. Histogram of population within-sample allele frequencies for all sites after removing loci with a 









Figure 3.10. Complexity of infection estimates from THE REAL McCOIL with 30,000 total runs with 
10,000 burn-in runs.   
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Figure 3.13. Principal component analysis. The first two principal components using all filtered, 




Figure 3.14. Principal component analysis. The first two principal components using filtered, monoclonal 




Figure 3.15. Per-locus percentage contributions to principal component 1. Chromosomes 1-14 are 
arranged from top to bottom. Pfcrt is indicated with the orange star on chromosome 7 and dhps is 





Figure 3.16. Per-locus percentage contributions to principal component 2. Chromosomes 1-14 are 
arranged from top to bottom. Pfcrt is indicated with the orange star on chromosome 7 and dhps is 




Figure 3.17. Per-locus percentage contributions to principal component 3. Chromosomes 1-14 are 
arranged from top to bottom. Pfcrt is indicated with the orange star on chromosome 7 and dhps is 




Figure 3.18. Per-locus percentage contributions to principal component 4. Chromosomes 1-14 are 
arranged from top to bottom. Pfcrt is indicated with the orange star on chromosome 7 and dhps is 




Figure 3.19. Per-locus percentage contributions to principal component 5. Chromosomes 1-14 are 
arranged from top to bottom. Pfcrt is indicated with the orange star on chromosome 7 and dhps is 




Figure 3.20. Extended haplotype extending 50 kb upstream and downstream of dhps 581, all 
samples.  Dhps 581 is position 550,117 and highlighted in red. Abbreviations: 0/0: wild-type call (purple), 




Figure 3.21. Extended haplotype extending 50 kb upstream and downstream of dhps 581, 581G 
samples. Red dot by sample name indicates 581G extended haplotype originating from DRC/East 
Tanzania. Green dot by sample name indicates 581G extended haplotype originating from Ghana. Dhps 
581 is position 550,117 and highlighted in red. Abbreviations: 0/0: wild-type call (purple), 0/1: mixed call 




Figure 3.22. Extended haplotype extending 50 kb upstream and downstream of dhps 581, A581 
samples. Dhps 581 is position 550,117 and highlighted in red. Abbreviations: 0/0: wild-type call (purple), 




Figure 3.23. Extended haplotype extending 50 kb upstream and downstream of dhps 581, Kinshasa 
samples. Red dot by sample name indicates 581G extended haplotype originating from DRC/East 
Tanzania. Dhps 581 is position 550,117 and highlighted in red. Abbreviations: 0/0: wild-type call (purple), 




Figure 3.24. Extended haplotype extending 50 kb upstream and downstream of dhps 581, Bas-Uele 
samples. Dhps 581 is position 550,117 and highlighted in red. Red dot by sample name indicates 581G 
extended haplotype originating from DRC/East Tanzania. Abbreviations: 0/0: wild-type call (purple), 0/1: 




Figure 3.25. Extended haplotype extending 50 kb upstream and downstream of dhps 581, Sud-Kivu 
samples. Red dot by sample name indicates 581G extended haplotype originating from DRC/East 
Tanzania. Purple dot by sample name indicates A581 extended haplotype originating from DRC/East 
Tanzania. Abbreviations: 0/0: wild-type call (purple), 0/1: mixed call (green), 1/1: mutant call (yellow), N/A: 




Figure 3.26. Extended haplotype extending 50 kb upstream and downstream of dhps 581, Ghana 
samples. Green dot by sample name indicates 581G extended haplotype originating from Ghana. Blue 
dot by name indicates A581 extended haplotype originating from Ghana. Dhps 581 is position 550,117 
and highlighted in red. Abbreviations: 0/0: wild-type call (purple), 0/1: mixed call (green), 1/1: mutant call 




Figure 3.27. Extended haplotype extending 50 kb upstream and downstream of dhps 581, East Tanzania 
samples. Red dot by sample name indicates 581G extended haplotype originating from DRC/East 
Tanzania. Dhps 581 is position 550,117 and highlighted in red. Abbreviations: 0/0: wild-type call (purple), 




Figure 3.28. Extended haplotype extending 50 kb upstream and downstream of dhps 581, West 
Tanzania samples. Dhps 581 is position 550,117 and highlighted in red. Abbreviations: 0/0: wild-type call 




Taken together, the extended haplotypes in the 100 kb surrounding the dhps 581 locus in our 
sample set do not conclusively demonstrate a hard selective sweep for the 581G variant arising from a 
single geographic origin. In the case of a hard selective sweep, we would have expected to see 
significant linkage disequilibrium between the 581G variant and other variants within the genomic region, 
forming an uninterrupted haplotype. Instead, several other patterns emerged when examining samples by 
their geographic origin and dhps 581 status. First, the 50 kb region downstream of the dhps 581 locus 
demonstrates a high degree of variation when comparing samples with differing 581 variants and 
locations, consistent with a high level of recombination in this region. Upstream of the dhps 581 locus, we 
did not observe a single conserved haplotype among the 581G samples but rather multiple extended 
haplotypes from different locations. This is consistent with previous literature describing the spread of 
dhps variants conferring sulfadoxine resistance in sub-Saharan Africa as a history of multiple geographic 
origins of sulfadoxine resistance with ongoing soft selective sweeps occurring on different genetic 
backgrounds  [172]. With respect to the dhps 581G variant, we are presently unable to conclude whether 
this variant descends from a single ancestral origin that has undergone significant recombination over 
time or arose multiple times on different genetic backgrounds. The interpretation of selection in this gene 
is also complicated by the likely repeated sweeps occurring in the gene over time due to the sequential 
accumulation of point mutations as resistance increased. This process obscures the signatures of 
selection at the gene. Future planned phylogenetic clustering analysis and additional sequencing will be 
helpful in gaining additional insight into the relatedness of these parasite strains. 
There are several possible explanations for why, despite the increasing prevalence of 581G 
variants in the DRC in recent years, we do not see evidence of a hard selective sweep at this locus 
[299,306]. First, Coartem (artemether + lumefantrine) has replaced SP as a first-line antimalarial, limiting 
the use of SP to IPTp and off-label uses. This change in drug usage has likely weakened the selective 
pressure for 581G variants, while concurrently inducing selective pressure at other loci to confer 
resistance to more widely-used artemisinin combination therapies. Additionally, malaria transmission 
remains high in the DRC, leading to a high frequency of mixed infections containing multiple parasite 
strains. In these mixed infections, parasites containing 581G variants must compete within the same host 
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with parasites that are wild-type at the locus. There is some evidence of fitness costs for dhps variants 
including 581G, including in vitro competition assays and observational studies that show increasing wild-
type dhps allele frequencies after the withdrawal of SP as a first line antimalarial [310–312]. This 
suggests that parasites with 581G variants likely face multiple competing selective pressures, with 
positive selection driven by sulfadoxine use in IPTp balanced against negative fitness costs. Overall, our 
results are most consistent with a soft selective sweep where 581G variants are being selected for in the 
context of standing variation.  
The results of the principal component analysis of our sample set are consistent with previous 
findings that show geographic clustering of parasite populations between east and west Africa [299]. 
Further, we observed additional clustering within the DRC, demonstrating that while there is significant 
overlap between these populations, regional variation can still be detected. However, when assessing 
genome-wide contributions to population structure, we did not observe contributions of dhps or pfcrt as 
has previously been described in similar parasite populations [299]. The likeliest explanation for this 
difference is the smaller number of samples (93 vs. 1,382) and larger number of loci (1,079 vs. 33,481) in 
this study compared with Verity et al. 
The estimated COIs for our sample set by location were consistently lower than reported in Verity 
et al., including overall (1.522 vs. 2.2), Ghana (1.50 vs. 1.55), Tanzania (1.55 vs. 2.17), and DRC (1.49 
vs. 2.23). Of interest, COI can be related to transmission intensity, as additional infectious bites increase 
the likelihood of mixed infections by different parasite strains [297]. However, the COIs of our sample set 
are not representative of local parasite populations because convenience sampling and PCR screening 
for 581G samples prior to whole-genome sequencing introduces selection bias. 
The principal strengths of this study include the use of samples collected between 2015-2017, 
providing an updated view of antifolate resistance from Verity et al. between 2013-2015. This study also 
includes samples from similarly diverse geographic locations spanning east and west Africa. Additionally, 
our use of whole-genome sequencing rather than molecular inversion probes or other amplicon-based 
methods provided a higher resolution view of the regions surrounding the dhps locus. However, the main 
limitations of this study were the low number of samples and convenience sampling method, which 
makes it difficult to draw broad conclusions about trends in antifolate resistance in the DRC.  
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Given the importance of antifolate use in preventive malaria therapies, continued monitoring of 
anti-folate resistance is needed. Evaluating the evolutionary forces driving mutation in the dhps gene 
provides an opportunity to improve our understanding of the origins and spread of sulfadoxine resistance. 
While this study did not detect signs of selection or geographic differentiation of mutant linages, continued 
study is warranted given the clear changes in prevalence of the mutation in Eastern DRC.  
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CHAPTER 4: DISCUSSION AND DIRECTIONS 
4.1 Key Findings 
In the second chapter of this dissertation, we describe the design and validation of several novel 
SHERLOCK assays to detect, differentiate, and genotype Plasmodium parasites. Our novel species-
differentiation SHERLOCK assays for P. falciparum, P. vivax, and pan-Plasmodium species performed 
similarly to PCR with limits of detection significantly below parasitemias typically seen in uncomplicated 
malaria. We also designed a novel SNV-detection assay to detect the dhps 581G variant in P. falciparum 
associated with high-level sulfadoxine resistance. Beyond testing our assays on plasmids or genomic 
DNA from laboratory parasite strains, we were the first group to validate our novel SHERLOCK assays on 
large panels of well-characterized clinical isolates. The results of these validation experiments are 
promising and demonstrate the potential of SHERLOCK as a modality to diagnose infectious diseases 
and detect drug-resistant variants. 
In the third chapter of this dissertation, we describe a whole-genome sequencing approach to 
measuring the impact of the dhps 581G variant on P. falciparum population structure within the DRC. In 
contrast with other recent work, we did not detect a significant contribution to population structure from 
the dhps locus. We then examined the extended haplotype surrounding the dhps locus and failed to 
detect evidence of a recent hard selective sweep. Rather, we observed the dhps 581G variant on multiple 
extended haplotypes, consistent with either 1) soft selective sweeps at this locus or 2) degeneration of 
hard selective sweeps by recombination over the decade since the mutation emerged. Understanding the 
spread of this mutation is important for malaria control efforts because of it is associated with reduced SP 
efficacy in both SMC and IPTp. Thus, further studies in this area are warranted. 
Together, these chapters highlight both the importance of antimalarial resistance surveillance and 
the potential for SHERLOCK to play an important role in this field in the future. The combination of rapid 
low-cost detection of antimalarial resistance polymorphisms that can be used on large numbers of 
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samples in a timely manner, followed by deeper genomic interrogation to understand their emergence 
and spread could be an impactful approach to antimalarial resistance surveillance. Though this is the 
achievable goal, the tools described herein require additional optimization before this combination is “field 
ready.” In the last section of this dissertation, there are additional considerations surrounding our work 
that merit further discussion, namely the steps needed to fully translate SHERLOCK and other CRISPR-
based diagnostics from the bench to the bedside and the use of point-of-care nucleic acid diagnostics 
more generally, especially in low-resource settings. 
4.2 Improving SHERLOCK and other CRISPR-based diagnostics for point-of-care testing and drug 
resistance surveillance 
Improvements to SHERLOCK that would facilitate its widespread use as a point-of-care nucleic 
acid test fall into the categories of sample extraction, reaction conditions, assay endpoint, and workflow 
integration. First, in its current form SHERLOCK typically requires some form of sample extraction. While 
SHERLOCK can use serum or urine as a direct input, serum requires separation from whole blood, urine 
may not be suitable for diagnosing all infectious diseases, and more complex samples such as whole 
blood require more intensive processing [276]. Compared with antigen-based RDTs for malaria that use 
blood collected with a fingertip lancet as an input, any extraction step adds complexity, time, reagents, 
instruments, and cost to each test. In our research, we used extraction methods optimized for recovering 
DNA from dried blood spots and would thus not be optimal for a clinical setting. One incremental 
improvement in this respect is the use of rapid thermal lysis and extraction protocols, such as heating 
unextracted diagnostic samples to obliterate nucleases (HUDSON) [313]. These protocols involve 
incubating samples in the presence of reducing and chelating agents at 37-95°C for 10-30 minutes to 
disrupt cell membranes and denature and inhibit nucleases. HUDSON has been directly tested in 
combination with SHERLOCK, and offers advantages over column-based extraction methods in most 
respects relevant towards a more clinically-useful diagnostic. However, although these extraction 
methods are simplified, they may still be too complex and labor-intensive for resource-limited settings. 
Incorporating an extraction-free or self-contained sample treatment method is necessary to make 
SHERLOCK and other CRISPR-based diagnostics truly point-of-care and capable of competing with 
current RDTs.  
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When considering how to improve the SHERLOCK reaction itself, the categories of 
preamplification, assay design and multiplexing should be considered. Canonically, SHERLOCK uses 
RPA or RT-RPA for preamplification and to append a T7 promoter sequence to the amplicon, which is 
necessary for subsequent in vitro transcription. However, the use of RPA in SHERLOCK has several 
drawbacks. First, we were unable to reproduce the one-pot SHERLOCK reaction despite numerous 
attempts, and instead used a two-step method that was effective but introduced additional time and 
complexity. Additionally, RPA reagents are exclusively sold by the company TwistDx, which in our 
experience has been unreliable in fulfilling orders in a timely manner. RPA is also expensive; at a list 
price £240.00 for 96 reactions it represents a significant contribution to overall reaction cost, although that 
can be reduced by a factor of five by splitting RPA reactions in the two-step SHERLOCK method we 
employed [314]. While it is theoretically possible to synthesize RPA enzymes in-house, that would require 
significant expertise, infrastructure, and economies of scale to be viable. Another option is replacing RPA 
with LAMP or PCR, which has been done for SARS-CoV-2 [315]. While this alleviates some RPA-specific 
concerns, it cannot be combined with Cas13a detection due to differing incubation temperatures and 
does little to reduce overall complexity of the assay. Nevertheless, Cas13a detection preceded by LAMP 
and PCR preamplification may be useful as a resource-intensive yet ultrasensitive diagnostic where other 
molecular methods are insufficient. 
Ultimately, the best approach to solving the preamplification problem in CRISPR-based 
diagnostics is to do away with it entirely and detect nucleic acids with Cas nucleases directly. In an 
exciting development, this was recently accomplished in a Cas13a-based diagnostic for SARS-CoV-2 
[277]. This assay is capable of detecting as few as 31 copies/µL SARS-CoV-2 RNA as well as RNA 
extracted from clinical isolates extracted from nasal swabs. To improve the sensitivity of the assay in the 
absence of preamplification, the authors used a multiplexed crRNA pool targeting SARS-CoV-2 RNA as 
well as optimized fluorescent probes to generate maximum signal in the presence of activated Cas13a. 
Unlike SHERLOCK, this assay has the added advantages of being quantitative, having a reaction time of 
30 minutes with faster results for higher viremias, and using a mobile phone camera combined with a 
basic fluorometer as a detector. While this assay was designed using the RNAse Cas13a, the same 
principles can be applied to Cas12 for DNA-based detection of other pathogens. Altogether, this assay is 
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an extremely promising proof-of-concept and is a significant advancement in moving CRISPR-based 
diagnostics towards being more point-of-care.  
Improving CRISPR-based diagnostics will also require using genomic data and clinical isolates to 
inform crRNA sequence design. For example, we experienced cross-reactivity between our P. vivax 
SHERLOCK assay and P. knowlesi despite the presence of four mismatches between the crRNA and 
target region, albeit in positions that are known to be less important for binding efficiency. This highlights 
the importance of testing multiple crRNAs for each assay against closely-related pathogens as well as 
those that are likely to present similarly in a clinical context. Another example of the importance of 
sequence variations on assay performance is the design of the Cas12a-based P. ovale diagnostic 
published by Lee et. al [275]. In this assay, the crRNA targets a region of the 18s rRNA that varies 
between P. ovale curtisi and P. ovale wallikeri, but was only validated on a single plasmid DNA source 
commonly used as a laboratory reference. We hypothesize that if these assays were tested against a 
diverse panel of clinical isolates, they would experience decreased performance against P. ovale wallikeri 
due to the presence of a two-nucleotide deletion present in the second and third positions of the crRNA 
target region, which are known to be important for binding efficiency [239]. This scenario demonstrates 
the importance of using high-quality genomic data to inform crRNA design as well as validating assays 
against diverse panels of clinical isolates as we did for our P. falciparum and dhps 581G SHERLOCK 
assays. 
While CRISPR-based diagnostics possess many advantages as a method for detecting SNVs 
conferring drug resistance, one limitation of these methods is the requirement to have knowledge of the 
SNV of interest in advance. In contrast to exploratory whole-genome sequencing methods, CRISPR-
based diagnostics require custom-designed crRNAs to target SNVs and that must first be validated in a 
laboratory setting. However, the relative strengths and weaknesses of whole genome sequencing and 
CRISPR-based diagnostics suggest complementarity rather than substitution in the detection of emerging 
SNVs. In this scenario, portable whole-genome sequencing methods would be used initially to identify 
novel SNVs in response to an outbreak of a drug-resistant pathogen. This information could then be used 
to design crRNAs targeting that locus, which could then be rapidly incorporated into existing CRISPR-
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based diagnostic platforms and validated. To close the loop, these SNV-detection CRISPR-based 
diagnostics could then be deployed back to the regions of outbreak and used to inform response efforts. 
For SHERLOCK SNV detection applications, future assay design and interpretation needs to 
account for variations in assay performance that occur with target nucleic acid concentration and mixed 
infections. For our dhps 581G SNV-detection assay, we observed that signal strength correlated with 
parasitemia for 581G samples in contrast with A581 samples, which were consistently negative across all 
parasitemias. While we were fortunate to have designed an ultra-specific 581G-detecting crRNA, this was 
unexpected; many of the other dhps 581G-detecting crRNAs that we tested had significant activity 
against wild-type variants, as do other SHERLOCK SNV-detection assays described elsewhere [240]. 
The combination of variable signal strength with target nucleic acid concentration and mutant/wild-type 
cross-reactivity poses a serious challenge for the design and interpretation of SNV-detection SHERLOCK 
assays because in clinical isolates, pathogen concentrations can vary greatly and infections often contain 
mixtures of mutant and wild-type pathogens. In cases where an ultra-specific mutant-detecting crRNA 
cannot be designed, both a wild-type and mutant detection assays need to be conducted for each sample 
and compared to produce a ratio that can be used to determine genotype.  
The ability to detect multiple targets is a major advantage of SHERLOCK and other CRISPR-
based diagnostics that should be utilized in future assay development. This is accomplished by using 
multiple Cas nucleases from different species including Cas13a, Cas13b, and Cas12a that have different 
sequence preferences for their collateral nuclease activity [242]. Fluorescent probes with different 
sequences and fluorophores can be used to take advantage of these differing activities to produce a 
fluorescent signal at a different wavelength for each target nucleic acid. The possible uses for multiplexed 
CRISPR-based diagnostic assays are limited only by imagination: for example, a community-acquired 
pneumonia assay that targets the most common bacterial and viral pathogens and uses a minimally-
processed sputum sample as input. Another advantage of multiplexing would be to combine SNV-
detection assays into a single reaction in addition to simply detecting the presence of a pathogen. While 
more replication and validation is needed on multiplexed CRISPR-based diagnostics, especially using 
complex clinical isolates, these types of assays are a promising direction for the technology moving 
forward. 
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The detection aspect of CRISPR-based diagnostics is another domain that would benefit from 
improvements in the direction of simplicity and affordability. For our research, we used a multi-use 
fluorescent plate reader setup that cost several thousand dollars in upfront costs, which is impractical for 
most resource-limited settings. One approach to address this is the use of small and inexpensive 
fluorometers, such as those used by Fozouni et al. in their direct Cas13a detection experiments described 
earlier [277]. Fluorometers have the advantage of providing quantitative signals, which can be useful for 
applications such as SNV detection and determining pathogen burden. Another method for detecting 
CRISPR-based diagnostics is lateral flow, which has already been applied to SHERLOCK [242]. Lateral 
flow platforms have the advantage of being disposable and requiring no additional detector, but provide a 
qualitative signal that is best served for determining the presence or absence of a pathogen. Given the 
strengths and weaknesses of fluorescence and lateral flow detection methods, it is likely that both will 
play complementary roles in the future of CRISPR-based diagnostics depending on the goal of the 
particular assay.  
Finally, CRISPR-based diagnostics will benefit greatly from engineering improvements that 
integrate sample processing, nuclease activation, and detection into a single device. Presently, CRISPR-
based diagnostics are still best viewed in comparison to other molecular diagnostics such as PCR, and in 
that respect they offer some technological improvements but have not yet become transformational. For 
instance, while SARS-CoV-2 SHERLOCK assays exist and received Emergency Use Authorization, the 
vast majority of COVID-19 testing is presently conducted by PCR or antigen-based methods [316]. Fully-
integrated CRISPR-based diagnostics similar to HRP-2 based RDTs would require less training and time 
to operate and benefit from the lower cost and higher consistency that comes from economies of scale. 
One possible example of this on the horizon is the Internal Splint-Pairing Expression Cassette Translation 
Reaction (INSPECTR) product in development by Sherlock Biosciences [317]. While specific details are 
scarce, INSPECTR is described as using Cas nucleases to detect nucleic acid with high sensitivity and 
specificity from unprocessed samples in under an hour and at low cost.  
While time will tell if INPECTR lives up to these lofty promises, the realization of fully point-of-care 
nucleic acid testing would revolutionize infectious disease diagnostics and drug resistance surveillance, 
especially along the dimensions of cost, time, and accessibility. Modern clinical microbiology labs are 
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expensive to build and require highly-trained personnel to operate, and point-of-care nucleic acid testing 
has the potential to replace many of these assays with less expensive alternatives. Less expensive 
testing also creates the possibility of using testing in ways that are not currently feasible, such as frequent 
prophylactic testing in hospitalized patients to detect and treat infections earlier. Many current diagnostics 
are also time-consuming, taking at best several hours and at worst days to weeks to return results. Rapid 
nucleic acid diagnostic testing would provide results sooner, allowing clinicians to tailor antimicrobial 
treatment sooner, leading to improved outcomes and the decreased spread of antimicrobial resistance. 
Methods for detecting SNVs associated with antimicrobial resistance similarly require a high degree of 
resources and skilled labor, and point-of-care SNV detection would be a boon in the response to 
outbreaks of drug-resistant pathogens. Last, point-of-care nucleic acid testing will improve the 
accessibility of molecular testing by facilitating the creation of assays for infectious diseases that are 
difficult to diagnose with current methods or require current molecular methods that are cost-prohibitive. 
Moving forward, improvements to point-of-care nucleic acid diagnostics should not focus on developing 
niche assays for use in high-resource clinical laboratories, but rather moving this technology closer to 
patients in resource-limited settings who will benefit from it the most. 
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